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resumo 
 
 
A doença pulmonar obstrutiva crónica (DPOC) é uma das doenças 
inflamatórias mais comuns das vias aéreas e uma das principais causas de 
morbidade e mortalidade em todo o mundo. A doença é caracterizada por uma 
limitação persistente do fluxo aéreo, geralmente progressiva. As respostas 
inflamatórias crónicas e imunes desempenham papéis fundamentais no 
desenvolvimento e progressão da DPOC. A inflamação é uma resposta 
protetora normal, mas na DPOC esta inflamação é amplificada. Várias células 
inflamatórias, seus mediadores e enzimas participam na resposta inflamatória 
na DPOC. A reabilitação respiratória é um componente fundamental da gestão 
da doença pulmonar obstrutiva crónica. Ela é projetada para melhorar a 
condição física e psicológica de pessoas com doenças respiratórias crónicas e 
para promover a adesão a longo prazo do comportamento que melhora a 
saúde. O objetivo principal deste trabalho foi contribuir para a compreensão do 
papel das células iNKT na patologia da DPOC. Além disso, também 
pretendemos explorar o efeito da reabilitação respiratória nas células iNKT em 
pacientes com DPOC. Análises clínicas e imunológicas foram feitas em 
pacientes com DPOC (n=7), pacientes com DPOC que realizaram reabilitação 
respiratória (n=4) e controlos saudáveis com idade e género idêntico aos 
doentes (n=14). Os participantes foram estudados duas vezes, com um 
intervalo de 12 semanas. Foram estudados os seguintes parâmetros clínicos: 
índice de massa corporal, percentagem de massa gorda, função pulmonar, 
força dos músculos respiratórios, força muscular isométrica, teste das cinco 
repetições sentar-levantar, teste de avaliação da DPOC e questionário da 
dispneia. As células iNKT foram estudadas em termos de percentagem, 
fenótipo, citotoxicidade e produção de citocinas. Não foi observada nenhuma 
alteração na percentagem de células iNKT, seus subconjuntos e produção de 
citocinas no sangue periférico de pacientes com DPOC em comparação com 
os controlos. Os nossos resultados sugeriram que as células iNKT de 
pacientes com DPOC podem ter uma diminuição na ativação precoce pela 
redução da expressão do CD69. Foi também sugerida uma redução na 
capacidade citotóxica em doentes. A reabilitação respiratória não pareceu 
afetar a redução da expressão do CD69, mas pareceu contribuir para o 
aumento da citotoxicidade das células iNKT e desempenhar um papel na 
melhoria do defeito citotóxico. Este é o primeiro estudo que conduziu uma 
extensa análise de correlações entre variáveis clínicas para a DPOC e 
variáveis imunológicas. Os resultados das nossas correlações indicaram que 
algumas células podem estar associadas a uma melhoria no estado de saúde 
do paciente e outras com o agravamento da DPOC. Este foi um estudo 
exploratório, e mais investigações sobre este tema são necessárias para 
fortalecer as conclusões. 
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abstract 
 
Chronic obstructive pulmonary disease (COPD) is one of the most common 
inflammatory diseases of the airways and a leading cause of morbidity and 
mortality worldwide. The disease is characterized by a persistent airflow 
limitation, generally progressive. Chronic inflammatory and immune responses 
play key roles in the development and progression of COPD. The inflammation 
is a normal protective response, but in COPD this inflammation is amplified. 
Several inflammatory cells, their mediators and enzymes participate in the 
inflammatory response in COPD. Pulmonary rehabilitation is a core component 
of chronic obstructive pulmonary disease management. It is designed to 
improve the physical and psychological condition of people with chronic 
respiratory disease and to promote the long-term adherence of health-
enhancing behavior. The main aim of this work was to contribute for 
understanding the role of iNKT cells in COPD pathology. In addition we also 
aimed to explore the effect of pulmonary rehabilitation on the iNKT cells in 
patients with COPD. Clinical and immunological analysis were done in patients 
with COPD (n=7), patients with COPD performing pulmonary rehabilitation 
(n=4) and age- and gender-matched healthy controls (n=14). Participants were 
studied twice, with an interval of 12 weeks. The following clinical parameters 
were studied: body mass index, body fat percentage, pulmonary function, 
respiratory muscle strength, quadriceps muscle strength, five time seat to 
stand, COPD assessment test and modified medical research council. The 
iNKT cells were studied in terms of percentage, phenotype, cytotoxicity and 
cytokine production. No alteration in percentage of iNKT cells, their subsets 
and cytokine production were observed in the peripheral blood of patients with 
COPD in comparison with controls. Our results suggested that iNKT cells from 
patients with COPD might have a decrease in early activation by reduction of 
CD69 expression. A reduction in cytotoxic capacity in patients was also 
suggested. Pulmonary rehabilitation did not seem to affect the reduction of 
CD69 expression, but seemed to contribute to the increase in iNKT cell 
cytotoxicity and might have a role in improving the cytotoxic defect. This is the 
first study that conducted an extensive correlation analysis between clinical 
variables for COPD and immunological variables. Findings from our 
correlations indicated that some cells might be associated with an improvement 
in the health condition of the patient, and others with the worsening of COPD. 
This was an exploratory study, and further research on this topic is warranted 
to strengthen conclusions. 
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1. Introduction
3 
 
1.1.  Chronic Obstructive Pulmonary Disease 
Chronic obstructive pulmonary disease (COPD) is one of the most common 
inflammatory diseases of the airways [1] and a leading cause of morbidity and mortality 
worldwide [2]. It is a chronic adult disease [3], affecting approximately 14% of individuals 
aged 65 years old or older, independently of exposure history, and it is responsible for 
19.9% of adults hospitalizations aged 65–75 years old [4]. 
The disease is defined as a preventable and treatable condition and can be characterized 
by persistent airflow limitation that is not fully reversible [5], [6]. The airflow limitation is 
generally progressive and associated with an enhanced chronic inflammatory response in 
the airways due to exposure of the lungs to noxious particles or gases [5], mainly caused 
by cigarette smoking [7]. Although tobacco is the most known and studied risk factor of 
COPD, there are other factors that can cause and contribute to the disease, such as genetic, 
ageing, gender, growth and development of the lung, environmental pollutants, 
occupational dust, vapours and fumes, asthma, chronic bronchitis, infections and 
socioeconomic status (poverty) [5], [8]. The best documented genetic risk factor linked to 
COPD is a severe hereditary deficiency of α1-antitrypsin, a major circulating inhibitory of 
serine proteases. Low concentrations of this enzyme, particularly in combination with 
smoking or other environmental exposures, increases the risk of parenchymal destruction 
leading to COPD. This hereditary deficiency is present in 1–3% of patients with the 
disease [9]. 
 
Pathology and pathogenesis of chronic obstructive pulmonary disease 
Even though COPD is recognized to have important systemic manifestations, such as 
cardiovascular events, systemic inflammation and alterations of metabolism, which may 
contribute to the disease severity in individual patients, its principal pathological changes 
occur in the lungs [5], [10], [11]. 
The inflammation is a normal protective response to the inhaled toxins, but in COPD 
this inflammation in the lungs, particularly in the small airways is amplified. Generally, the 
inflammation mediated by T cells and structural changes in the airways tend to increase 
with the severity of disease. This inflammation persists for years, even after smoking 
cessation, through unknown mechanisms, although it is believed that autoantigens and 
persistent microorganisms may play a role [5], [12], [13]. Lung inflammation is further 
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modified by two other processes involved in the COPD pathogenesis: the oxidative stress 
and an excess of proteases (Figure 1) [5], [13]. Infections of the respiratory tract by viruses 
and bacteria also contribute to amplify the lung inflammation and the pathogenesis of 
COPD [14], [15]. 
COPD is characterized by a specific pattern of inflammation involving increased 
numbers of macrophages, neutrophils, B and T lymphocytes (mostly CD8
+
, but also CD4
+
) 
in the lungs [5], [12], [16]. These inflammatory cells release inflammatory mediators and 
enzymes, which interact with structural cells in the airways, pulmonary vasculature and 
lung parenchyma [5], [17]. The increased neutrophil number can result in an increased 
release of proteinases and oxidants, leading to imbalances that induce lung destruction 
[12], [18]. Macrophages secrete several inflammatory mediators, including growth factors, 
such as transforming growth factor-β, which stimulate fibroblast proliferation causing 
fibrosis in the small airways; proinflammatory cytokines that increase inflammation, and 
chemokines, which attract circulating cells into the lungs perpetuating the inflamation. 
Additionally, macrophages promote the recruitment and activation of monocytes and T 
lymphocytes [1], [18]. The role of T cells in COPD pathogenesis is not fully understood 
[19], however, it is known that T lymphocytes are increased in the lung parenchyma and 
airways, with an increase in CD8:CD4 ratio. CD8 cells may be cytotoxic [12], because of 
its potential to secrete tumor necrosis factor, granzymes and perforins, and to activate the 
Fas–Fas ligand apoptotic pathway, which leads to alveolar wall destruction [20]. B 
lymphocytes, important agents in the acquired immune system, are also increased in 
pathogenesis of the COPD, maybe as a response to chronic infection of the airways [12], 
[18], [21]. Inflammatory response is enhanced and maintained due to pro-inflammatory 
mediators, such as: leukotriene B4, interleukin-8, tumor necrosis factor α (TNFα), 
macrophage inflammatory protein-1α released by inflammatory and structural cells, 
attracting more inflammatory cells and creating a positive inflammatory loop [10]. In 
conclusion, COPD is developed by the actions of both innate and acquired immune 
responses [10], [22]. 
In COPD the oxidative metabolism is over-activated, because of oxidants from 
cigarette smoke and internal production of oxidants by phagocytes, such as neutrophils and 
macrophages, which are involved in bronchial inflammation [18], [23], [24]. 
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Proteases activity is regulated by production and release of antiproteases [18], 
however, in COPD there is an imbalance of proteases and antiproteases, which is the 
consequence of increase production/activity of proteases and inactivation/reduce 
production of antiproteases [12]. This imbalance is caused by cigarette smoke and 
inflammation itself, which leads inflammatory cells to secrete proteases and inhibit the 
activity of several antiproteases, such as α1-antitrypsin,  by oxidative stress [12], [18].  
 
 
Figure 1. The mechanism of COPD pathogenesis. Dashed bars represent inhibitory effects. Adapted by 
MacNee [12]. 
 
Pathophysiology of chronic obstructive pulmonary disease 
The underlying pathogenic mechanisms of COPD lead to pathological changes, which 
result in physiological alterations, such as airflow limitation and air trapping, gas exchange 
abnormalities, mucous hypersecretion and ciliary dysfunction, pulmonary hypertension, 
exacerbations, and systemic effects [5], [12]. 
Airflow obstruction (Figure 2) is induced by inflammation, fibrosis and luminal 
exudates in small airways, which are correlated with the reduction of Forced Expiratory 
Volume in one second (FEV1) and FEV1/FVC (Forced Vital Capacity) ratio, and possibly 
with the accelerated decline in FEV1, typical of the disease [12], [17]. The peripheral 
airway obstruction progressively traps air during expiration leading to hyperinflation. Loss 
of the lung elastic recoil, by destruction of alveolar walls, and the destruction of alveolar 
support, also are involved in the airflow obstruction [12]. The hyperinflation reduces 
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inspiratory capacity and can occur when the lung is at rest, called static hyperinflation or 
during exercise, denominated by dynamic hyperinflation [12], [25]. In patients with 
COPD, hyperinflation contributes to dyspnea, i.e., a subjective experience of breathing 
discomfort that consists of qualitatively distinct sensations that vary in intensity, and 
limitation of exercise capacity, characteristics of the disease [26].  
The anatomical changes found in patients with COPD, such as severe obstruction and 
ventilatory muscle impairment, cause reduced ventilation, leading to gas exchange 
abnormalities. These abnormalities result in arterial hypoxemia with or without 
hypercapnia. As the disease progresses, the gas transfer for oxygen and carbon dioxide 
becomes worse [12], [27]. 
Hypersecretion results from the metaplasia, increased number of goblet cells and 
enlarged size of bronchial submucosal glands as a consequence of chronic airway 
irritation, caused by cigarette smoke and other noxious agents and gases [5], [12], [28]. 
Squamous metaplasia of epithelial cells induce ciliary dysfunction that results in an 
abnormal mucociliary escalator and difficulty in expectorating [12]. 
In patients with COPD, exacerbations of the disease are frequent and are caused by 
infection with bacteria or/and viruses, air pollution, alterations of ambient temperature or 
unknown factors. Exacerbations, i.e., “a worsening of the patient’s respiratory symptoms 
that is beyond normal day-to-day variation and leads to change in medication”, adopted by 
Gold 2016 [5]; are characterized by an increase inflammation (increase of the neutrophils 
number and in some mild exacerbations, increase of eosinophils number).  The physiologic 
changes typical of COPD become more severe in exacerbations, with an increased 
hyperinflation and airflow limitation, difficulties in pulmonary gas exchange because of 
increased inequality between ventilation and perfusion which can result in hypoxemia, 
mucous hypersecretion, oedema and bronchoconstriction [5], [12], [29]. Other diseases, 
like thromboembolism, pneumonia and acute cardiac failure can aggravate or mimic 
COPD exacerbations [5].  
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Figure 2. Pathological changes that are underlying to small airway obstruction in COPD. Adapted by Barnes 
[30]. 
 
Symptoms and diagnosis of chronic obstructive pulmonary disease 
Predominant symptom in COPD is the persistent and slowly progressive breathlessness 
(dyspnea) with efforts [1], [31]. Nevertheless, other symptoms are also typical of the 
disease, such as cough, sputum production, wheezing, and chest tightness. COPD 
symptoms can be variable from day-to-day, and the patient does not need to display the set 
of symptoms to have the disease [5], [31], [32]. In severe and very severe COPD, 
symptoms like fatigue, weight loss and anorexia are frequent [5], [33] and can also be a 
sign of other diseases, including tuberculosis and lung cancer [5]. Depression and anxiety 
are also commonly present in patients with the disease [34]. 
A clinical diagnosis of COPD should be done if the patient is older than 40 years old 
and displays the following criteria: typical symptoms of the disease (such as, progressive 
and persistent dyspnea, chronic cough or sputum production), family history of COPD and, 
exposure history to risk factors for the disease (e.g., cigarette smoke and noxious particles 
or gases) [5]. Lung function measured with spirometry is the most accurate diagnostic test 
to evaluate patients who have clinic context of COPD [35]. Through FEV1 and FVC, 
which are the key lung function variables, it is possible to classify the stage and severity of 
airflow limitation in COPD (Table 1).  According to the GOLD classification, COPD is 
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diagnosed to a patient who has the FEV1/FVC ratio less than 70% [5]. In order to minimize 
variability, spirometry ought to be performed after the administration of a short-acting 
inhaled bronchodilator in an appropriate dose [5]. 
 
 
 
 
 
 
 
 
A good diagnosis of COPD should not be based only on the disease severity measured 
by lung function, but also in the evaluation of current level of patient’s symptoms, 
exacerbation risk and presence of comorbidities [5]. Thus, it is important to consider other 
measurements, such as Modified British Medical Research Council (mMRC) 
questionnaire, which is a simple measure of breathlessness and adequate for assessment of 
symptoms, COPD Assessment Test (CAT), and COPD Control Questionnaire (CCQ), 
which evaluate the health status and the clinical control in patients and number of 
exacerbations and hospitalizations per year [5].  
Other tests, like Chronic Respiratory Questionnaire (CRQ) [36] and St. George’s 
Respiratory Questionnaire (SGRQ) [37] are more accurate to measure the quality of life 
and the health status of patients with COPD, but are also too time consuming to be used in 
routine clinical practice [5]. 
Several additional investigations can be considered as part of the diagnosis and 
assessment of the disease, including imaging (chest X-ray and computed tomography, 
Figure 3), lung volumes and diffusing capacity by body plethysmography or helium 
dilution lung volume measurement, oximetry and arterial blood gas measurement, α-1 
antitrypsin deficiency screening (serum concentration <15-20% of the normal value is 
highly suggestive of this deficiency) and exercise testing (e.g., walking tests and cycle or 
treadmill ergometry test) [5]. 
 
Stage and Severity Definition 
I - Mild  FEV1/FVC < 0.70;  FEV1 ≥80% predicted 
II - Moderate FEV1/FVC < 0.70;  50% ≤ FEV1 < 80% predicted 
III - Severe FEV1/FVC < 0.70;  30% ≤ FEV1 < 50% predicted 
IV - Very Severe FEV1/FVC < 0.70;  30% < FEV1 predicted 
Table 1. Classification of severity of airflow limitation in COPD, based on postbronchodilator FEV1. 
Adapted from GOLD [5]. 
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Figure 3. Computed tomography of chest that shows a parenchymal pulmonary destruction with a loss of 
alveolar attachments in left lobe of a patient with COPD. Adapted by Desai and Steiner [38]. 
 
Therapeutic options for chronic obstructive pulmonary disease 
Although COPD does not have cure, it can be controlled. The main goal of the 
treatment focuses in delaying the disease progression. If therapy is appropriate, it can 
reduce the symptoms, improve health status, as well as exercise tolerance [5]. 
In patients who smoke, the smoking cessation must be the first step of any therapy, 
because it is the intervention most capable to influence the COPD natural history [5].  
Secondly, patients can use pharmacologic therapy to reduce symptoms and improve 
their general health status. Pharmacologic therapy includes medications like 
bronchodilators, vaccines, antibiotics, mucolytic and antioxidant agents, 
immunoregulators, antitussives, vasodilators, narcotics, between others. However, the most 
usual pharmacologic therapy for patients with COPD is the treatment with bronchodilator 
medications [5]. Bronchodilator medications increase the FEV1 or change other 
spirometric variables, normally by modifying airway smooth muscle tone, thereby 
promoting the widening of the airways and reduction of dynamic hyperinflation at rest and 
during exercise with improvements in exercise endurance time [5], [39], [40]. The 
bronchodilators often used by patients with COPD are beta2-agonists, anticholinergics, 
methylxanthines, corticosteroids and phosphodiesterase-4 inhibitors [5].  
Genetic augmentation therapy, more precisely α-1 antitrypsin augmentation therapy 
should be applied only in young patients with severe hereditary α-1 antitrypsin deficiency 
and established parenchymal destruction [5]. 
Besides pharmacologic therapeutic options, there is a non-pharmacologic therapy to 
patients with COPD, called pulmonary rehabilitation, which is considered a core 
component of COPD management [5], [41]. 
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Other treatments, such as oxygen therapy and ventilatory support can also be applied 
under specific conditions of disease with clinical benefits to patients with COPD. In more 
severe cases, surgery or even lung transplantation may be considered [5]. 
 
1.1.1. Pulmonary rehabilitation as a core component of chronic obstructive 
pulmonary disease management  
Pulmonary rehabilitation is designed to improve the physical and psychological 
condition of people with chronic respiratory disease and to promote the long-term 
adherence of health-enhancing behaviors. So, pulmonary rehabilitation is a comprehensive 
intervention based on a thorough patient assessment followed by patient-tailored therapies, 
which include, but are not limited to, exercise training, education, and behavior change. 
This intervention is implemented by an interdisciplinary team, including physicians, 
physiotherapists, respiratory therapists, nurses, psychologists, exercise physiologists, 
behavioral specialist, occupational therapists, nutritionists, and social workers, between 
others [42]. The aims of pulmonary rehabilitation include reducing symptom burden, 
maximizing exercise performance, promoting autonomy, increasing physical and 
emotional participation in daily activities, improving health-related quality of life, and 
effecting long-term health-enhancing behavior change [42], [43]. Rehabilitation therapy 
does not directly improve lung mechanics or gas exchange, but optimizes the function of 
other body systems, minimizing the effect of lung dysfunction [41]. An effective 
rehabilitation program has to be extended by a minimum length of 6 weeks. However, the 
longer the patient performs the program, more effective will be the results [5], [44].  
Pulmonary rehabilitation programs vary considerably in their components, but 
generally include patient assessment, exercise training, education, psychosocial support 
and nutritional counselling [5], [42], [43]. The exercise component of pulmonary 
rehabilitation increases inspiratory volume and reduces dynamic hyperinflation (occurs 
when heavy exercise training decreases the ventilatory requirement and respiratory rate, 
prolonging the time allowed for expiration) resulting in a mitigation of dyspnea when the 
person is performing tasks [41]. Exercise also increases skeletal-muscle function by induce 
changes in muscle biochemistry, increasing aerobic function of the muscles of ambulation, 
delaying fatigue and resulting in increased exercise tolerance [41], [42], [45]. Depression 
and anxiety are also reduced maybe as a result of increased exercise capacity and 
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participation in daily activities (Figure 4) [41]. Various modes of training are required for 
improvements in cardiorespiratory endurance, strength, and/or flexibility. In general the 
training can include endurance training, interval training, resistance training, 
neuromuscular electrical stimulation, and respiratory muscle training [42]. The educational 
component of this intervention focuses on collaborative self-management and behavior 
change, by providing information and knowledge concerning the disease; building skills, 
like goal setting, problem solving and decision making; developing action plans that allow 
individuals to better recognize and manage the disease and focuses on modifying 
nutritional intake and smoking patterns; adhering to medication and regular exercise; and 
using effective breathing techniques and energy-saving strategies [42], [45]. 
 
Figure 4. Effects of exercise training as part of a pulmonary rehabilitation for patients with COPD. Adapted 
by Casaburi et al. [41]. 
 
1.2.  The immune system in chronic obstructive pulmonary disease 
Chronic inflammatory and immune responses play key roles in the development and 
progression of COPD [46]. The inflammation is a normal protective response, 
nevertheless, in COPD this inflammation is amplified [12]. Several inflammatory cells, 
their mediators and enzymes participate in the inflammatory response in COPD, by interact 
with structural cells in the airways, lung parenchyma and pulmonary vasculature [5], [16], 
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[46]. Some of the cells that participate in the pathogenesis of COPD are B cells and T cells 
[3]. CD8
+
 T cells have been implicated in COPD pathogenesis mainly indeed their 
numbers in lung parenchyma and small airways correlate inversely with FEV1, which is the 
clinical measure most frequently used to define COPD severity [47]. Currently, natural 
killer (NK) cells and natural killer T (NKT) cells have gained increasing attention. NK and 
NKT cells are two types of killer cells that have the ability to directly kill target cells [3]. 
NK cells are less specific lymphocytes, being their activation controlled by a balance of 
signals from stimulatory receptors and inhibitory receptors [48]–[50]. NK cells are a 
lymphoid population defined by not express CD3 and include surface expression markers, 
like CD56, in humans and NK1.1, in mouse. Human NK cells can thus be defined 
phenotypically as CD3
-
CD56
+
 and murine NK cells as CD3
-
NK1.1
+
 [51], [52]. 
But contrary to NK cells, NKT cells express a T cell receptor generated by somatic 
DNA rearrangement, which is a hallmark of acquired immune system cells. Thus, by 
sharing characteristics of both NK and T cells, NKT cells have a unique role in bridging 
innate and acquired immunity [53]. NKT cells recognize glycolipid antigens presented by 
the non-polymorphic major histocompatibility complex class I-like molecule CD1d [54], 
[55]. When a glycolipid antigen binds to CD1d, the antigen/CD1d complex binds to the 
TCR of NKT cells and the recognition occurs [56]. After recognizing glycolipids, NKT 
cells are stimulated to secrete large amounts of cytokines and chemokines, which regulate 
their movement and activation [57]. NKT cells have been linked to the regulation of 
immune responses in a broad range of diseases, like autoimmunity, inflammation, 
infectious diseases and cancer [54], [57]. NKT cells are divided into two subsets based 
upon differences in TCR characteristics [58]; Type I NKT cells, or invariant NKT (iNKT) 
cells, which express a TCR composed of an invariable α chain associated with a limited 
repertoire of β chains, recognizing glycolipid antigens, and type II NKT cells, which 
express an unbiased TCR repertoire with variable α and β chains, recognizing a range of 
hydrophobic antigens, including sulfatide and lysophosphatidylcholine [59]. 
Invariant NKT cells are the best-known and studied subset of CD1d-restricted cells.  
 
1.2.1. Invariant natural killer T cells  
Invariant natural killer T cells express a TCR with an invariant α-chain, Vα14-Jα18 
in mice and  Vα24-Jα18 in humans, paired with certain TCRβ chains, Vβ8.2, Vβ7 or Vβ2 
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in mice and Vβ11 in humans (Figure 5) [57], [60]. The most widely acknowledged iNKT 
cell antigen is the glycolipid α-galactosylceramide (α-GalCer), which is a synthetic form of 
a chemical purified from the marine sponge Agelas mauritianus [61]. This lipid is also 
used for the identification of iNKT cells, through its loading on CD1d tetramers [62]. 
Nevertheless, there are other glycolipid antigens to iNKT cells, such as bacterial and 
mammalian glycolipids [56], [63], [64]. The monoclonal antibody 6B11, a combination of 
an anti-Vα24 antibody with an anti-Vβ11 antibody, and CD1d tetramers loaded with 
PBS57 are also used to identify iNKT cells by binding to their semi-invariant TCR. 
However, some researchers do not use any of the specific reagents referred above to 
identify iNKT cells, using instead CD3 monoclonal antibody in combination with CD56 or 
CD16 monoclonal antibody. For this reason, this cells can not be called iNKT cells, so they 
are named NKT-like cells [60], [65], [66]. 
iNKT exhibit an activated or memory phenotype by constitutively expressing a 
variety of markers, including CD44, CD69 and CD122 [53]. They are widely distributed 
into the body and can be found in the liver, spleen, peripheral blood, lung, bone marrow, 
fat tissue, gastrointestinal tract and skin [67], [68]. Humans usually have a low frequency 
of iNKT cells, ranging from ~0.01% to 1%, amongst peripheral blood T cells, as well as an 
increased variability between individuals in comparison with mice, which makes the study 
of iNKT cells in humans very challenging [69]–[71]. 
Invariant NKT cells express diverse surface receptors. Some of them, such as 
CD161 (NK1.1 in mouse), are common to NKT and NK cells. Others, such as CD4 and 
CD8 are also found in other T cells [53]. 
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Figure 5. Overall scheme of iNKT cell activation mediated by the semi-invariant TCR recognition of 
glycolipids bound to CD1d at the surface of antigen presenting cells. Adapted by Kaer [72]. 
 
In humans, three different subsets of iNKT cells can be defined according to CD4 
and CD8 expression: CD4
+
, CD4
-
CD8
-
 or also called double-negative (DN) and CD8
+
. 
However,  in mice, iNKT cells are mostly CD4
+
 or DN [73], [74]. Whereby the absence of 
CD8
+
 iNKT cells suggested that these cells could be deleted in the thymus, but was later 
shown that CD8
+
 iNKT cells exist in mice, although at a quite low percentage [75]. The 
percentage of CD4/CD8 iNKT cell subsets is very variable among individuals, i.e., CD4
+
 
and DN iNKT cells are the most common subsets in humans, with CD4
+
 varying between 
17-53%, DN between 19-63% and CD8
+
, which is the less common subset, representing 
only 5-25% of the iNKT cell population [74], [76]–[84]. These frequencies are altered in a 
variety of conditions [68].  
After activation, iNKT cells rapidly secrete large amounts of T-helper 1 (Th1), Th2, 
and/or Th17-specific cytokines and exhibit cytolytic activities. CD4
+
 iNKT cells release 
Th1 cytokines, including interferon-γ (IFN-γ) and TNF-α, and TH2 cytokines, such as 
interleukin-4 (IL-4), IL-13 and IL-10. In contrast DN and CD8
+
 iNKT cells mainly 
produce TH1 cytokines and display cytotoxic activity [56], [60], [85]. Efficient production 
of cytokines, mostly IL-4, is important to regulate the immune system by inhibition of TH1 
and induction of TH2 response [86]. The capacity of iNKT cells to rapidly produce copious 
amounts of cytokines upon antigenic stimulation, endows these cells with potent 
immunomodulatory activities [53]. Thus, cytokines, chemokines and surface molecules 
expressed by iNKT cells deeply influence many other cell types [67], as represented in 
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Figure 6. iNKT cells have the capacity to activate NK cells, macrophages, T cells and 
promote their differentiation, B cells leading to antibody production and memory 
responses, and dendritic cells that express CD1d establishing a bidirectional activation. 
Furthermore, iNKT cells promote neutrophil recruitment and regulate their supressive 
activities, as well as suppress regulatory T (Treg) cells [67], [87]. 
 
Figure 6. Interactions between iNKT cells and other types of immune cells. DC – dendritic cell. Adapted by 
Lawrenczyk et al. [87]. 
 
iNKT cells develop in the thymus and most of them leave the thymus in an 
immature stage and fulfill their terminal maturation in the periphery [69]. The development 
of the iNKT cells begins with the expression of the invariable TCR, which induce the 
differentiation pathway of these cells. Invariant NKT cells are positively selected by the 
interaction of the TCR with CD1d molecules expressed by thymocytes [88]. iNKT cell 
maturation in mice is composed by four stages. The first stage (stage 0) is defined by a 
population of CD24
+
CD44
-
NK1.1
-
 cells. Subsequently, in stage 1, CD24 is downregulation 
and the cells start to proliferate, maintaining low expression of CD44 and NK1.1 
(CD24
−
CD44
−
NK1.1
−
). While still proliferating, CD44 is upregulated 
(CD24
−
CD44
+
NK1.1
-
) in stage 2. In addition, at this stage some cells downregulate CD4, 
constituting the DN iNKT cell lineage. The last maturation stage (stage 3) is characterized 
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by the upregulation of NK1.1 and other NK cell lineage markers (CD24
−
CD44
+
NK1.1
+
), 
which generally occurs after migration to the periphery [59], [67], [88]–[90]. 
As in mice, iNKT cell maturation process in humans is also completed at the 
periphery, in which cells increase the expression of CD161 (human equivalent to NK1.1). 
The earliest detectable NKT cell precursors in humans are CD4
+
 and CD161
-
 cells, 
whereby CD4
−
 and CD161
+
 NKT cells arise at later developmental stages [59]. iNKT cells 
are potently activated when they encounter APCs with exogenous or endogenous antigens 
loaded in CD1d molecules. Depending on the type of antigen, three different pathways can 
lead to iNKT cell activation process [67], [91]. Direct pathway, in which the antigen is 
initially internalized and loaded in CD1d molecules or directly loaded in the CD1 
molecules present at the cell surface, resulting in CD1d-lipid complex. This complex 
present at the surface of the APC interacts with the TCR of the iNKT cell, inducing its 
activation (Figure 7A). Direct + indirect pathway is characterized by binding of some 
antigens to Toll-like receptors present at the APC surface, starting a cascade of events that 
promotes the loading of endogenous antigens in CD1d molecules and IL-12 secretion. This 
process results in a double activation of iNKT cells by IL-12 and by CD1d interaction with 
TCR (Figure 7B). In the indirect pathway, there is no TCR mediated recognition of the 
antigen, i.e., the antigen only promotes IL-12 secretion by APCs (Figure 7C) [91].  
 
 
Figure 7. Different pathways leading to iNKT cell activation during infection. A – Direct pathway; B – 
Direct + Indirect pathway; C – Indirect pathway. Adapted by Brigl and Brenner [91]. 
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1.2.2. Cytotoxic markers in lymphocytes 
A pathway used by cytotoxic T lymphocytes (CD8
+
), NK and NKT cells to destroy 
pathogenic cells occurs by exocytosis of granule components towards the target cell, 
delivering a lethal hit of cytolytic molecules [65], [92], [93]. Cigarette smoke succeeds in 
damaging the physical barrier of mucosal epithelium and the innate immune system, and it 
induces effector mechanisms of the immune system, which are particularly cytotoxic to the 
patient with COPD [94]. Many cells have the potential to cause the damage seen in the 
airways of patients with COPD, including three distinct classes of human killer cells 
referred above, i.e., CD8
+
 T cells, NK cells and NKT cells [95], [96]. NK and NKT cells 
can be a potent source of cytokines and cytotoxic molecules, and an increase in their 
number or improper effector function could contribute to COPD pathology [47]. While 
cytotoxic CD8
+
 T cells have been widely studied in COPD, the role of cytotoxicity of NK 
and NKT cells is attracting increased attention [3]. 
Granzyme B, CD107a and CD158b are some molecules used to monitor the 
cytotoxic response of lymphocytes [65], [92], [93]. 
 
Granzyme B 
Granzymes are a family of serine-proteases, which have their catalytic activity 
dependent on a serine residue at the active site. In humans, five granzymes with differing 
substrate specificity have been identified. However, Granzyme B has the strongest pro-
apoptotic activity of all granzymes. Through its caspase-like ability to cleave substrates at 
aspartic acid residues, Granzyme B activates pro-caspases, thus inducing apoptosis 
initiating  [97]. CD8
+
 T lymphocytes and NK cells use the exocytosis of Granzyme B 
granules, stored in the cytoplasm of the effector cell, to cause targeted cell apoptosis [98], 
[99]. Granzyme B is also expressed at high levels in activated iNKT cells [100], [101]. 
Granzymes could play an important role in the lung tissue destruction witnessed in COPD 
and contribute to the pathogenesis of the disease. This destruction may occur from either 
direct cell-cell interactions or exogenously present granzyme [99].  
Peripheral blood of patients with COPD presents an increased frequency of T 
lymphocytes, NK and NKT-like cells expressing Granzyme B [102], [103]. In addition, the 
proportion of NK and NKT-like cells are increased in bronchoalveolar lavage fluid 
(BALF) in COPD, associated with increased NK cytotoxicity and increased expression of 
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Granzyme B by both cell types [103]. It was also found a significant correlation between 
Granzyme B expression in BALF-derived T-cells and apoptosis of bronchial epithelial 
cells [102]. Therefore, granzyme-mediated apoptosis can be a mechanism of lung injury in 
COPD [102]. However, other study found that the proportion of NK and NKT-like cells in 
peripheral blood from smokers with COPD was reduced, with defective cytotoxic effector 
cell function and with reduced proportions expressing Granzyme B [99]. 
 
CD107a 
CD107a is a lysosomal transmembrane protein, highly glycosylated, with a 40-kDa 
backbone and 17 predicted N-glycosylation sites, as well as 9 O-glycosylation sites. The 
intralysosomal part of CD107a contains two highly N-glycosylated domains, which are 
separated by a proline and serine-rich hinge, highly O-glycosylated [104], [105]. 
The expression of CD107a on the cell surface has been reported as a marker of 
cytotoxic degranulation in CD8
+
 T lymphocytes and NK cells [106], [107]. This cytotoxic 
marker was shown to be upregulated on the cell surface after stimulation. CD107a is a 
sensitive marker of NK cell functional activity [107]. It is also known that activated iNKT 
cells have an upregulation of CD107a expression [108]. In the presence of cigarette smoke, 
associated with most cases of COPD, the upregulation of CD107a on iNKT cells is 
inhibited [108]. Cigarette smoke also inhibits CD107a expression in NK cells without 
affecting other NK cell markers [109]. 
 
CD158b 
NK cell receptors can be divided into both activating receptors and inhibitory 
receptors, such as CD158b. CD158b belongs to the family of killer cell immunoglobulin-
like receptors  [110] and contains long cytoplasmic regions [65], [111] with pairs of 
immunoreceptor tyrosine-based inhibitory motifs  that release inhibitory signals [111]. The 
presence of these receptors is not exclusive to NK cells, since NKT cells also express these 
similar receptors [112]. Inhibitory receptors discriminate malignant from healthy cells by 
surveying the surface expression of self-MHC class I molecules, thereby preventing the 
attack of NK and NKT cells against healthy cells [3], [110]. In patients with COPD, the 
expression of CD158b on NK and NKT-like cells is increased [3]. Besides that, there are 
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evidences that the frequency of CD158b in NK cells is negatively correlated with FEV1% 
prediction and FEV1/FVC [3]. 
 
1.3.  iNKT cells in the context of chronic obstructive pulmonary disease  
COPD pathology is associated with innate and acquired inflammatory immune 
responses [17]. iNKT cells may play a role in the pathogenesis of chronic airway disease, 
but there are few studies done in COPD (Table 2). A decreased frequency of iNKT cells in 
peripheral blood of patients with stable COPD when they stained the cells with 6B11 
monoclonal antibody comparing with healthy controls was observed, however, when the 
iNKT cells were stained with α-GalCer-loaded CD1d-tetramer, no significant alterations 
were found [113]. On the contrary, according to other investigation, patients with COPD 
present increased iNKT cell frequency in the peripheral blood when compared to healthy 
subjects [114]. Moreover, a mouse model of COPD induced by chronic cigarette smoke 
exposure showed a rise in activated iNKT cell numbers in the lung. The contribution of 
these cells to disease pathology is highlighted by experiments in CD1d
-
/
-
 and Jα18-/- mice, 
which lack all NKT cells and or specifically lack iNKT cells respectively. These animals 
have suppressed several features of COPD, such as inflammation and parenchymal 
destruction [114]. In addition, repeated intranasal administration of the iNKT cell agonist 
α-GalCer in mice leads to high levels of IL-4 and features of COPD, such as airway 
inflammation with significant increases in infiltration of macrophages and CD8
+
 T cells, as 
well as the proinflammatory cytokines IL-6 and TNF-α [115]. These mice also show 
mucus production, pulmonary fibrosis and parenchymal destruction with loss of alveolar 
attachments and decrease of elastic recoil. Neutralization of IL-4 reduces parenchymal 
destruction induced by α-GalCer, which indicates the importance of iNKT cells in the 
pathogenesis of COPD by an IL-4 dependent mechanism [115]. Further, other study 
concluded that mice infected with Sendai virus develop chronic lung disease and airway 
hypersensitivity similar to COPD in humans and such chronic manifestation was 
dependent IL-13 from macrophages and iNKT cells [116]. The frequency of iNKT cells 
analyzed in induced sputum, airway biopsy and bronchoalveolar lavage do not have 
significant changes between patients with COPD and healthy people [117]. 
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Table 2. Summary of iNKT cells studies in chronic obstructive pulmonary disease. 
 
Species / Type of sample Results References 
Human / peripheral blood 
Patients with stable COPD display lower frequency of iNKT 
cells in the peripheral blood than controls when the cells were 
stained with the 6B11 monoclonal antibody  
[113] 
Human / peripheral blood 
No significant differences in frequency of iNKT cells in the 
peripheral blood of patients with stable COPD comparing with 
controls, when the cells were stained with α-GalCer-loaded 
CD1d-tetramer 
[113] 
Human / peripheral blood 
Patients with COPD display higher frequency of  iNKT cells in 
peripheral blood than controls 
[114] 
Mice / intranasal 
Repeated intranasal administration of the iNKT cell agonist α-
GalCer leads to high levels of IL-4 and features of COPD 
[115] 
Mice / lung tissue 
Mice infected with Sendai virus develop chronic lung disease 
and airway hypersensitivity similar to COPD in humans and 
such chronic manifestation was dependent IL-13 from 
macrophages and iNKT cells 
[116] 
Human / induced sputum; 
airway biopsy; 
bronchoalveolar lavage 
No significant differences in frequency of iNKT cells in induced 
sputum, airway biopsy and bronchoalveolar lavage between 
patients with COPD and controls 
[117] 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
2. Aims 
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The aims of this work were: 
 to study the invariant natural killer T (iNKT) cells in patients with chronic 
obstructive pulmonary disease (COPD); 
 to investigate the effect of pulmonary rehabilitation on the iNKT cells in patients 
with COPD. 
 
To achieve these aims we studied the iNKT cells in terms of percentage, phenotype, 
cytotoxicity and cytokine production in three groups, i.e., patients with COPD, patients 
with COPD who performed a pulmonary rehabilitation (COPD-PR), and age- and gender-
matched healthy controls. In addition we analyzed clinical parameters, relevant for 
respiratory function, in the 3 groups of participants to integrate the immunological and 
clinical data.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Materials and Methods  
 
 
 
 
 
 
 
 
 
 
 
 
27 
 
3.1.  Ethics 
Ethical approval was previously obtained from the Ethics and Deontology Committee 
at the University of Aveiro, Portugal (Appendix I). 
 
3.2.  Design and recruitment 
A pre-post exploratory study design was conducted, based on collection of 
sociodemographic data, anthropometric measurements, subjective and objective measures 
of clinical evaluation, including blood sample collection from patients with chronic 
obstructive pulmonary disease. Three different groups of participants were recruited; group 
1 was composed of four patients with COPD who performed pulmonary rehabilitation 
(COPD-PR), group 2 included seven patients with COPD who never underwent pulmonary 
rehabilitation (COPD) and group 3 included fourteen age- and gender-matched healthy 
controls (control). The COPD-PR group was recruited through the pulmonary 
rehabilitation program conducted at Respiratory Rehabilitation and Research Laboratory 
(Lab3R), School of Health Sciences (ESSUA), University of Aveiro. Patients with COPD 
were identified by the pulmonologists of the Centro Hospitalar Baixo Vouga and 
physicians from the Agrupamento dos Centros de Saúde do Baixo Vouga. The controls 
were recruited from Castelo de Paiva, and included healthy volunteers, and healthy people 
attending to social institutions, i.e., Santa Casa da Misericórdia de Castelo de Paiva, 
Castelo de Paiva Day Care Center, Senior University of Castelo de Paiva and Associação 
de Solidariedade Social de Souselo. Permission was granted by the directors of these 
institutions. The study was explained and detailed information was provided (Annex I) by 
the researcher (master student) to interested participants and written informed consent was 
obtained before any data collection (Annex II). Healthy volunteers were eligible if they: 
had > 40 years old; presenting spirometric values within the expected for their age, height 
and sex and normal clinical history, and were able to provide informed consent to 
participate in the study. Patients with COPD were eligible if they: had > 40 years old, 
diagnosis of COPD according to the guidelines defined by the Global Initiative for Chronic 
Obstructive Lung Disease [5], and were able to provide informed consent to participate in 
the study. Participants were excluded if they: had experienced an acute respiratory 
infection in the month prior to collection of data, present musculoskeletal impairment (e.g. 
scoliosis, limb amputation), cardiorespiratory, additional to the diagnosis of COPD (e.g. 
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asthma; heart failure), neurologic (e.g. sclerosis, neuromuscular disease) or cognitive 
impairment (e.g. dementias), and were bedridden or dependent on a wheelchair. To test the 
effects of the pulmonary rehabilitation in the COPD-PR group, two data collections were 
needed, one at baseline, before patients starting the pulmonary rehabilitation (called pre) 
and another after 12 weeks, in post-pulmonary rehabilitation (named post). Moments of 
data collection for the other two groups were similar to facilitate comparisons between 
groups (Figure 8). 
 
 
Figure 8. Overall design of the study. 
 
 
3.3.  Pulmonary rehabilitation 
The pulmonary rehabilitation attended by the COPD-PR group included exercise 
training (twice a week from 60 minutes each session) and psychosocial support and 
education (once every other week for 60 minutes), over a period of 12 weeks.  
 
Exercise training 
The exercise training was supervised by a physiotherapist. Sessions of exercise training 
were composed of: i) A warm-up and a cool-down period, which included range-of-
motion, stretching, low-intensity aerobic exercises and breathing techniques (5–10 min); ii) 
Endurance training (walking or cycling) at 60–80% of the average speed achieved during 
the 6-min walk test (15–20 min). The training intensity was adjusted according to the 
participant’s symptoms on the modified Borg scale, with a rating of 4–6 on perceived 
dyspnea/fatigue indicating adequate training intensity; iii) Strength training including 7 
exercises (2–3 sets of 10 repetitions) of the major upper and lower limb muscle groups 
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using free weights and ankle weights (15–20 min). The amount of weight was 50–85% of 
the 1-repetition maximum. The training progression was based on the two-for-two rule 
(load was increased when 2 additional repetitions could be performed on 2 consecutive 
sessions) and on the participant’s symptoms (modified Borg scale 4–6); iv) Balance 
training was based on proprioceptive activities with static and dynamic exercises using 
upright positions (10 min).  
 
Psychosocial support and education 
The psychosocial support aimed to help the family to manage the emotional demands 
of living with COPD, facilitate the communication within the family and with health/social 
services, and develop a sense of family identity, improving its cohesion. The education 
intended to provide information about COPD, increase the skills of the family in order to 
adjust and manage the disease, and promote adherence to therapy and healthy lifestyles. 
Psychosocial support and education was conducted by a multidisciplinary team, 
including physiotherapist, nurse, gerontologist, psychologist, and clinician. The 
professionals assumed the role of facilitators by supporting participants in their doubts, 
encouraging them to share experiences, normalizing emotions, and assuming an empathic 
attitude. Several didactic methods were used in the sessions, such as group discussions, 
home tasks, role playing, and brainstorming. 
 
3.4.  Outcome measures 
A structured questionnaire based on the International Classification of Functional, 
Health and Disability checklist [118] was used to collect sociodemographic, 
anthropometric, and objective and subjective clinical data from all participants of the 
study. Sociodemographic data included age, sex, academic qualifications, marital status 
and current occupation. General clinical data, smoking habits, physical activity, vital signs 
and oxygen saturation were collected.  
Anthropometric data involved weight and height measurements to calculate the body 
mass index (BMI) and the body fat percentage (BFP). Dyspnea and fatigue was assessed 
using the modified Borg scale [119] (see Annex III), activities limitation resulting from 
dyspnea was assessed with the modified British Medical Research Council (mMRC) 
questionnaire [120] (see Annex III) and lung function was assessed with a portable 
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spirometer (MicroLab 3500, CareFusion Corporation, Kent, UK), according to the 
international guidelines [121]. Quality of life was assessed using the self-reported COPD 
Assessment Test (CAT) [122] (see Annex III). Participants performed maximal knee 
extension efforts on dominant leg, during 6 seconds and quadriceps muscle strength 
(QMS) was measured using a hand-held dynamometer [7] (microFET2TM, Hoggan Health 
Industries, USA). Respiratory muscle strength, i.e., maximal static inspiratory (MIP) and 
expiratory mouth pressures (MEP) were measured using a portable mouth pressure meter 
(MicroRPM™, CareFusion Corporation, USA) [123]. To evaluate the lower limb muscle 
function and balance, the five-repetition sit-to-stand (5TSS) test was performed [124]. This 
test measures the time taken to stand five times from a sitting position (using a chair) as 
rapidly as possible, with the upper limbs crossed on the chest. Participants performed three 
repetitions of all practical tests, with at least 1 min rest between each repetition. 
These tests have been widely applied in patients with COPD and healthy subjects, in 
order to compare clinical state, limitations in daily life and quality of life among patients 
and healthy people [5], [123]–[131]. 
 
3.5.  Blood sample collection - Immunological analysis by characterization 
of peripheral blood iNKT cells  
Blood samples of the COPD and COPD-PR groups were collected by a nurse in the 
clinical area of the School of Health Sciences, at the University of Aveiro and blood 
samples of the controls were collected at the Policlínica de Castelo de Paiva, Santa Casa 
da Misericórdia de Castelo de Paiva, and Associação de Solidariedade Social de Souselo. 
A nurse collected from each patient 20mL of blood in ethylenediamine tetraacetic acid 
(EDTA) containing tubes which were sent to the Instituto de Investigação e Inovação em 
Saúde (i3S) to be processed. 
 
3.5.1. Peripheral blood mononuclear cells isolation 
Once the blood samples arrived at the lab, peripheral blood mononuclear cells 
(PBMCs) were isolated using Histopaque-1077® (Sigma-Aldrich, St. Louis, MO, USA) by 
density gradient centrifugation, under sterile conditions. The blood was carefully layered 
on the same quantity of Histopaque-1077® and centrifuged at 400xg for 30 min at room 
temperature (RT), without brake. After centrifugation it was possible to distinguish 
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different layers. PBMCs were located in a ring between the plasma and Histopaque-1077® 
(Figure 9). Firstly, the plasma was aspirated to a new falcon tube and centrifuged at 2500 
rpm for 30 min at 4ºC. Upon plasma centrifugation, the supernatant was stored into a new 
falcon tube at -20ºC. Secondly, PBMCs were collected and washed once by adding 10mL 
of phosphate buffered saline 1x (PBS 1x, see appendix II) and centrifuged at 250xg for 10 
min at RT.  After this centrifugation the PBMCs still contained remaining erythrocytes, 
which were lysed by incubating cells for 10 min with 10mL of ACK lysis solution (see 
appendix II). The cells were then washed again by adding 10mL of PBS 1x and centrifuged 
at 250xg for 10 min at RT. The supernatant was discarded and lastly, cells were washed 
once more with 10mL of PBS 1x and counted using Trypan Blue to determine PBMCs 
viability. Cells were diluted in necessary amount of Trypan Blue for each sample and were 
counted in a cell counting chamber (haemocytometer) using an inverted microscope.  
 
 
Figure 9.  Representative figure of PBMCs isolation using Histopaque-1077®. 
 
PBMCs were frozen in liquid nitrogen for posterior use (all samples of pre: 
controls, COPD and COPD-PR, and four of post: 3 COPD and 1 COPD-PR) or used 
immediately (remaining samples) for flow cytometry analysis and/or iNKT cell expansion 
and stimulation. The samples were frozen because the study was still being prepared and 
all the antibodies needed for experimental work were not available, as well as, by the fact 
that I was still in training, in order to learn the techniques used in this laboratory work. 
Samples of the three studied groups were analyzed by flow cytometry, including iNKT 
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cells percentage, phenotypic and cytotoxic profiles and only the remaining cells of COPD 
group and controls were used to perform the iNKT cell expansion, stimulation, and 
analysis of their cytokine production profile and cytotoxicity by flow cytometry. In the 
second blood collection (post) all samples of the three groups were used to analyze 
percentage, phenotype and cytotoxicity of iNKT cells by flow cytometry (Figure 10) so no 
expansion and subsequent analyzes was done. 
 
Figure 10. Global scheme of the processing of blood samples. 
 
Thawing PBMCs 
Cells which were preserved in liquid nitrogen were later thawed, but no more than 
2 cryovials at a time. The cells were melted in a 37ºC water bath and 1mL of RPMI 
10%iFBS (see appendix II) it was slowly added. The cells were then quickly transferred to 
a falcon tube containing 9mL of RPMI 10%iFBS and the empty vial was washed with 
RPMI 10%iFBS, transferring remaining cells to the falcon tube, which was centrifuged at 
1500 rpm, 5 min at RTº. Upon centrifugation, the cells were resuspended in 5mL of RPMI 
10%iFBS with 50g/mL of DNAse and incubated for 15 min at 37ºC, in order to avoid cell 
clumping. The cells were centrifuged and resuspended once more in 5mL of RPMI 
10%iFBS to finally count the cells using Trypan Blue. 
 
3.5.2. iNKT cells percentage, phenotype and cytotoxic analysis by flow 
cytometry  
Extracellular staining (The entire process was made at 4ºC, including centrifugations) 
Up to 1x10
6 
PBMCs were stained per well in a round-bottomed 96-well plate and 
centrifuged at 1200 rpm, for 2 min. The supernatant was rejected and cells were 
resuspended in the vortex and washed with 200l of 
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PBS/2%FBS/1%PenStrep/0.01%NaN3 (flow cytometry solution, see appendix II). Again 
the plate was centrifuged, the supernatant was rejected and the cells were once more 
resuspended in the vortex and stained with 25l of the antibody/tetramer mix diluted in 
flow cytometry solution for 20 min, at 4ºC, in the dark. After incubation, the cells that will 
be stained intracellularly were washed twice by adding 100-200l of flow cytometry 
solution, centrifuged at 1200 rpm for 2 min, the supernatant were rejected and the cells 
were resuspended in the vortex. The remaining cells were washed once more and fixed by 
adding 200l of PBS 1%formaldehyde (see appendix II) and transferred to FACS tubes 
(Falcon, BD Bioscience) also containing 200l of PBS 1%formaldehyde. PBMCs were 
kept at 4ºC in the dark until their acquisition on the flow cytometer. 
 
Intracellular staining (The entire process was made at RT, including centrifugations) 
Upon extracellular staining and two washings, cells were fixed by incubating with 
PBS 2%formaldehyde for 10 min, at RT, in the dark. Then, cells were centrifuged at 1200 
rpm for 2 min, at RT, the supernatant was discarded and PBMCS were permeabilized by 
incubating with 0.5%Saponin (Sigma-Aldrich, St. Louis, MO, USA) diluted in flow 
cytometry solution (see appendix II), for 5 min, in the dark. After incubation, cells were 
centrifuged again at 1200 rpm for 2 min, supernatant was discarded and PBMCs were 
resuspended in 25l of fluorochrome-labeled antibody diluted in flow cytometry solution 
with 0.5%saponin. After 30 min of incubation, at RT, in the dark, cells were washed twice 
with 0.5%saponin diluted in flow cytometry solution and once just with flow cytometry 
solution. The supernatant was always discarded and the cells were resuspended in 200l of 
PBS 1x and transferred to FACS tubes also with 200l of PBS 1x. 
 
3.5.3. iNKT cell expansion, stimulation and analysis of their cytokine 
production profile  
Remaining cells from the flow cytometry staining were used in iNKT cell 
expansion by culturing 1x10
6
 PBMCs per well in 2mL of RPMI 10%iFBS medium with 
100ng/mL of α-GalCer (Avanti polar lipids, Alabaster, AL, USA) at a concentration 
0.5x10
6
cells/mL in a 24-well plate. At day 1 of culture, 50U/mL of recombinant human IL-
2 (kindly provided by the National Cancer Institute, NCI, USA) was added to each well. 
On days 11-14 of expansion, cells were collected, counted and stimulated by culturing 
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1x10
6 
cells/well in a round-bottomed 96-well plate in 200l of RPMI 10%iFBS with 
25ng/mL Phorbol 12-myristate 13-acetate (PMA, Sigma-Aldrich, St. Louis, MO, USA), 
1µg/mL Ionomycin (Sigma-Aldrich, St. Louis, MO, USA) and 10µg/mL Brefeldin A 
(Sigma-Aldrich, St. Louis, MO, USA) for 5h before staining with cytokine-specific 
monoclonal antibodies. Cells for the compensation necessary to the acquisition on the flow 
cytometer were not stimulated. 
 
3.5.4. iNKT cell cytokine production profile and cytotoxic analysis by flow 
cytometry  
After expansion and stimulation cells were stained as described previously in point 
3.5.2; however the used staining mixtures were different.  
 
Antibodies used in flow cytometry 
All the used antibodies in flow cytometry are listed in Table 3. The human CD1d 
tetramer used was loaded with PBS57 and labelled with the fluorochrome phycoerythrin 
(PE), from the National Institute of Health tetramer core facility. 
All samples were acquired in a BD FACS Canto™ II flow cytometer, using the BD 
FACSDiva™ software (BD Biosciences, San Diego, CA, USA). Flow cytometry analyses 
were performed using the FlowJo software (FlowJo LLC, Ashland, OR, USA). 
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Table 3. Antibodies used in flow cytometry. 
PerCPCy5.5  Peridinin chlorphyll protein conjugated with Cy5.5; FITC – Fluorescein Isothiocyanate; PECy7 – Phycoerythrin 
conjugated with Cy7; APC – Allophycocyanin; APCeFluor 780 – Allophycocyanin conjugated with eFluor 780; bv510  Brilliant 
Violet 510; Alexa647  Alexa Fluor® 
 
3.6. Statistical analysis 
A code was assigned to each participant and the data was treated anonymously. 
Statistical analysis was performed using SPSS Statistics 22 (IBM Corporation, Armonk, 
New York) and graphs were plotted in GraphPad Prism 5 (GraphPad Software, La Jolla, 
CA, USA). The normality of data distribution was investigated with Shapiro-Wilk test and 
level of significance considered was set at p<0.05. 
 
Outcome measures analysis 
Descriptive statistics were used to describe the sample using mean and standard 
deviation for continuous data (i.e., age), median and interquartile range for ordinal (i.e., 
CAT and mMRC) and continuous non-normally distributed data (i.e., BMI, BFP, 
pulmonary function, MIP, MEP, QMS and 5TSS) and frequencies and percentages for 
categorical data (i.e., gender, academic qualification, marital status, occupation, smoking 
Antibody Clone Fluorochrome Brand 
Anti-human CD3 OKT3 PerCPCy5.5 eBioscience 
Anti-human CD56 MEM-188 FITC eBioscience 
Anti-human CD158b DX27 PECy7 Biolegend 
Anti-human CD69 FN50 APC eBioscience 
Anti-human CD8 RPA-T8 APCeFluor780 eBioscience 
Anti-human CD161 HP-3G10 eFluor450 eBioscience 
Anti-human CD4 OKT4 bv510 Biolegend 
Anti-human CD107a H4A3 PECy7 Biolegend 
Anti-human Granzyme B GB11 Alexa647 Biolegend 
Anti-human IFNgamma 4S.B3 PECy7 eBioscience 
Anti-human IL-4 8D4-8 APC eBioscience 
Isotype Control (Mouse IgG1 K) P3.6.2.8.1 PECy7 eBioscience 
Isotype Control (Mouse IgG1 K) P3.6.2.8.1 APC eBioscience 
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habits and spirometric classification of COPD). Kruskal-Wallis test was used to compare 
ordinal/continuous non-normally distributed data among groups. When significant 
differences were observed between groups, Mann-Whitney U test was used for multiple 
comparisons. Mann-Whitney U test was also used to compare QMS between COPD and 
COPD-PR groups. Chi-Square test was used for categorical measures.  
 
Immunological analysis 
Mean and standard deviation values were calculated and statistical significance was 
assessed by Unpaired T-test (for continuous normally distributed data) or Mann-Whitney 
U and Wilcoxon matched-pairs signed rank tests (for continuous non-normally distributed 
data). Unpaired T-test and Mann-Whitney U test was used to compare data between groups 
and Wilcoxon matched-pairs signed rank test was used to compare data from patients of 
COPD-PR between pre and post-pulmonary rehabilitation. 
 
Correlations analysis 
Correlations between clinical (i.e., MIP, MEP, 5TSS and pulmonary function) and 
immunological variables (i.e., T lymphocytes, iNKT cells, NK cells and cytotoxic markers) 
were performed using Spearman’s non-parametric rank correlation coefficient. The choice 
of these clinical variables for performed correlations is justified because they are the best 
measures addressed in this study, which characterize the COPD. The strength of the 
correlations was assessed using the criteria suggested by Mukaka et al. [132], (i.e., 0-0.30 
negligible correlation; 0.31-0.50 poor correlation; 0.51-0.70 moderate correlation; 0.71-
0.90 high correlation and 0.91-1 very high correlation).  
 
 
  
 
 
 
 
 
4. Results 
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4.1.  Sample characterization  
Table 4 shows the characteristics of all participants. Eleven patients with chronic 
obstructive pulmonary disease and fourteen healthy age- and gender-matched controls 
were included in this study. However, in the group of patients with COPD, we had two 
distinct groups; i.e., COPD group (n=7) composed by patients that were never treated with 
pulmonary rehabilitation, and the COPD-PR group (n=4), composed by patients that were 
naïve at the start of the study but performed pulmonary rehabilitation during 12 weeks 
during the course of the study. The control group was composed by nine males and five 
females and had a mean age of 64.2 years old (standard deviation of ± 9.6 years); the 
COPD group was composed by five males and two females and had a mean age of 62 
years old (standard deviation of ± 12.7 years); and the COPD-PR group was composed by 
three males and one female and had a mean age of 65.3 years old (standard deviation of ± 
4.3 years). From the 1
st
 to the 2
nd
 clinical assessment, we had two dropouts (one participant 
of the COPD group and one of the control group), thus twenty-three participants completed 
the clinical assessments. No significant differences in terms of age, gender, academic 
qualifications, marital status, occupation, smoking habits, body mass index (BMI) and 
body fat percentage (BFP) were found between the studied groups (Table 4). Lung 
function parameters, i.e., forced expiratory volume in one second (FEV1) predicted and 
ratio of forced expiratory volume in one second and forced vital capacity (FEV1/FVC, 
Tiffeneau index) were significantly different (p<0.05) from both groups of patients with 
COPD and age- and gender-matched controls, who displayed higher median values, as well 
as, higher values of interquartile range. The spirometric classification of COPD presented 
no significant difference between the two groups of patients. 
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Table 4. Sociodemographic and anthropometrical characterization of the studied groups. 
 
Characteristics 
Control 
(n=14) 
COPD 
(n=7) 
COPD-PR 
(n=4) 
pa value 
Age (years) 64.2 ± 9.6 62.0 ± 12.7 65.3 ± 4.3 0.849 
Gender, n (%)     
Male 9 (64.3) 5 (71.4) 3 (75) 
0.897 
Female 5 (35.7) 2 (28.6) 1 (25) 
Academic qualifications, n (%) 
No qualifications 0 0 0 
0.052 
1st Basic Education Cycle 5 (35.7) 3 (42.9) 1 (25) 
2nd Basic Education Cycle 2 (14.3) 1 (14.3) 0 
3rd Basic Education Cycle 1(7.1) 2 (28.6) 1 (25) 
High school 3 (21.4) 0 0 
Medium course 0 0 2 (50) 
University degree 3 (21.4) 0 0 
Marital status, n (%) 
Married/Cohabiting 9 (64.3) 4 (57.1) 3 (75) 
0.906 
Widowed 2 (14.3) 1 (14.3) 0 
Separated/Divorced 1 (7.1) 1 (14.3) 1 (25) 
Single 2 (14.3) 1 (14.3) 0 
Occupation, n (%)     
Employed 5 (35.7) 2 (28.6) 0 
0.373 Retired 9 (64.3) 5 (71.4) 4 (100) 
Unemployed 0 0 0 
Smoking habits, n (%)     
Never  6 (42.9) 2 (28.6) 1 (25)  
Former 6 (42.9) 2 (28.6) 2 (50) 0.668 
Current 2 (14.3) 3 (42.9) 1 (25)  
BMI (kg/m2) 24.3 [22.1 to 27] 25.8 [22.1 to 27.8] 29.8 [27.7 to n/a] 0.053 
BFP (%) 28.9 [20 to 34.3] 28.1 [20.4 to 34.3] 33.1 [26.1 to n/a] 0.602 
Pulmonary function     
FEV1 predicted (%) 97.5 [91.5 to 116.5]† 66 [36 to 78] 75 [73 to 79.3] 0.000* 
FVC predicted (%) 101 [90 to 118.8] 87 [74 to 97] 102 [87 to 106.5] 0.055 
FEV1/FVC 77 [74 to 80.5]† 64 [38 to 67] 57 [55 to 69.8] 0.001* 
Spirometric classification of COPD, n (%) 
GOLD A (Mild) --- 4 (57.1) 3 (75)  
GOLD B (Moderate) --- 0 1 (25) 0.309 
GOLD C (Severe) --- 2 (28.6) 0  
GOLD D (Very severe) --- 1 (14.3) 0  
a Kruskal-Wallis test used for continuous non-normally distributed measures; Chi-Square test used for categorical measures. 
COPD: Chronic Obstructive Pulmonary Disease; COPD-PR: Chronic Obstructive Pulmonary Disease-Pulmonary Rehabilitation; BMI: 
Body Mass Index; BFP: Body Fat Percentage; FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; 
FEV1/FVC: Tiffeneau index; GOLD: Global Initiative for Chronic Obstructive Lung Disease; n/a: not applicable. 
Data are presented as Mean values ± Standard deviation or Median values [interquartile range] unless otherwise indicated. *p <0.05. † 
significantly different from COPD and COPD-PR. 
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4.2.  Effect of pulmonary rehabilitation on clinical variables in patients with 
chronic obstructive pulmonary disease  
Results from the clinical variables obtained in the three studied groups, in the 1
st
 
clinical assessment (baseline/pre) and the 2
nd
 clinical assessment (post-pulmonary 
rehabilitation) are shown in table 5. Only COPD Assessment Test (CAT) presented 
significant changes (p<0.05), when compared COPD and COPD-PR groups to healthy 
controls. In the control group this clinical measure did not present differences between the 
1
st
/pre and the 2
nd
/post clinical assessment, while the COPD and COPD-PR groups 
presented different values with time. No other significant changes were observed between 
groups.  
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 Table 5. Clinical variables for chronic obstructive pulmonary disease in the studied groups taking into account the time (pre and post). 
 
Clinical Measures 
Control COPD COPD-PR Mean difference 
for control 
Mean difference 
for COPD 
Mean difference 
for COPD-PR 
p value 
Pre Post Pre Post Pre Post 
QMS (Kgf) --- --- 20.7 
[16.5 to 22] 
15.5 
[10 to 21.7] 
21.7 
[21 to n/a] 
13.1 
[10.6 to 16.4] 
--- -3.2 
[-9.8 to 3.1] 
-7.6 
[-8.9 to n/a] 
0.364
 a
 
MIP (cmH2O) 84 
[73 to 93.5] 
85 
[64 to 93] 
68 
[44 to 82] 
92 
[73.8 to 105.3] 
94 
[58 to 103.8] 
75 
[48.8 to 114.8] 
1 
[-7 to 12.5] 
14.5 
[8.8 to 37.8] 
-1.5 
[-33 to 17.3] 
0.074 
MEP (cmH2O) 122 
[87.8 to 132.3] 
114 
[93.5 to 142] 
128 
[86 to 172] 
149 
[95.8 to 164] 
108 
[104.3 to 148.5] 
123 
[82 to 132.5] 
-4 
[-13 to 11.5] 
6.5 
[-7.3 to 19.5] 
-11 
[-40 to 28.3] 
0.595 
5TSS (s) 6.5 
[5.3 to 7.2] 
6.2 
[5 to 8.2] 
6.6 
[5.3 to 8.9] 
7.9 
[5.3 to 8.9] 
6.1 
[4.3 to 10.1] 
6.7 
[5.1 to 7.9] 
0.1 
[-0.1 to 0,8] 
0.4 
[-1.1 to 1.9] 
0.6 
[-2.8 to 1.5] 
0.772 
CAT 0 
[0 to 1.5] 
0 
[0 to 1.5] 
8 
[4 to 9] 
6.5 
[4.5 to 12.7] 
8.5 
[4.3 to 16.5] 
11.5 
[5.3 to 20] 
0 
[-0.5 to 0]† 
2.5 
[-3.8 to 7.5] 
2 
[1 to 4.5] 
0.044* 
mMRC 0 
[0 to 0] 
0 
[0 to 0] 
1 
[1 to 1] 
1 
[0 to 1.3] 
1 
[0.3 to 1.8] 
1 
[0.3 to 1.8] 
0 
[0 to 0] 
-0.5 
[-1 to 0.3] 
0 
[0 to 0] 
0.192 
Pulmonary function           
FEV1 predicted (%) 97.5 
[91.5 to 116.5] 
100 
[89 to 118] 
66 
[36 to 78] 
65 
[40.8 to85] 
65 
[40.8 to 85] 
75 
[73 to 79.3] 
1 
[-5 to 4] 
-1.5 
[-7.3 to 5.5] 
-14.5 
[-24.5 to -3.8] 
0.111 
FVC predicted (%) 101 
[90 to 118.8] 
108 
[102 to 123.5] 
87 
[74 to 97] 
84 
[79 to 101] 
102 
[87 to 106.5] 
96 
[89 to 99.3] 
3 
[-6 to 9] 
1 
[-5.3 to 5.3] 
-6.5 
[-14 to 9.3] 
0.510 
FEV1/FVC 77 
[74 to 80.5] 
76 
[73.5 to 79.5] 
64 
[38 to 67] 
62.5 
[40.8 to 65] 
57 
[55.5 to 69.8] 
57 
[49 to 65] 
-1 
[-4.5 to 2] 
-0.5 
[-5.8 to 3] 
-5 
[-13.3 to 7] 
0.765 
 
 
Note: Comparisons were performed using Kruskal-Wallis test (continuous non-normally distributed measures), unless otherwise stated. 
a Mann-Whitney U test used for comparisons between mean difference for COPD and COPD-PR.  
COPD: Chronic Obstructive Pulmonary Disease; COPD-PR: Chronic Obstructive Pulmonary Disease-Pulmonary Rehabilitation; QMS: Quadriceps Muscle Strength; MIP: Maximal Inspiratory Pressure; MEP: 
Maximal Expiratory Pressure; 5TSS: Five Time Seat to Stand; CAT: COPD Assessment Test; mMRC: modified Medical Research Council; FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital 
Capacity; FEV1/FVC: Tiffeneau index; n/a: not applicable. 
Data are presented as Median value [interquartile range]. *p <0.05. †significantly different from COPD and COPD-PR.
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4.3.  Immunological analysis by characterization of peripheral blood iNKT 
cells in patients with chronic obstructive pulmonary disease 
To study the iNKT cells in the peripheral blood of patients with chronic obstructive 
pulmonary disease (COPD), PBMCs were stained with an antibody anti-human CD3 and 
the human PBS57-loaded CD1d tetramer and analyzed by flow cytometry. After defining 
the lymphocyte gate in the side scatter and forward scatter plot, T cells (CD3
+
) were 
selected and the percentage of CD1d-PBS57 tetramer positive cells (iNKT cells) within 
this gate was determined (Figure 11). 
 
 
Figure 11. Gating strategy used for the analysis of the percentage of iNKT cells by flow cytometry. 
 
In humans, the iNKT cell population can be divided in three subsets according to the 
expression of CD8 and CD4 molecules: CD4
-
CD8
+
 (CD8
+
), CD4
+
CD8
- 
(CD4
+
), and CD4
-
CD8
- 
(DN) [73], [74]. Figure 12 shows a representative example of the gating strategy used 
to define the CD8/CD4/DN iNKT subsets.  
 
 
Figure 12. Gating strategy used for the analysis of iNKT CD4/CD8/DN cell subsets percentage, determined 
by flow cytometry. 
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Besides CD4 and CD8 expression, iNKT cells also express a variety of molecular 
markers, such as CD161, CD56 and CD69
 
(Figure 13). The expression of these markers by 
iNKT cells was also analyzed in patients with COPD. 
 
 
Figure 13. Gating strategy used to analyze the expression of CD161, CD56
 
and CD69 on iNKT cells by flow 
cytometry. Tinted line corresponds to unstained and black line to stained sample. 
 
In non-activated iNKT cells, the expression of CD69 is low, and it is not possible to 
distinguish a positive and a negative population. Therefore, mean fluorescence intensity 
(MFI) was used to measure CD69 expression on iNKT cells. 
To study the cytotoxicity of iNKT cells, the following markers were used: CD158b, 
CD107a and Granzyme B. The gating strategy to analyze these markers is shown in Figure 
14. 
 
Figure 14. Gating strategy used for the analysis of cytotoxic markers in iNKT cells, determined by flow 
cytometry. Tinted line corresponds to unstained and black line to stained sample. 
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We also analyze NK cells (CD3
-
CD56
+
), as well as their expression of CD158b (Figure 
15). 
 
 
 
Figure 15. Gating strategy used for the analysis of the percentage of NK cells and the expression of CD158b
 
on these cells, determined by flow cytometry. NK cells were identified among peripheral lymphocytes and 
defined based on the expression of CD56 and the lack of CD3. Tinted line corresponds to unstained and 
black line to stained sample.  
 
4.3.1. Analysis of iNKT cells in chronic obstructive pulmonary disease 
The ex vivo blood iNKT cell percentage, iNKT subsets and markers of cytotoxicity 
were analyzed in patients with COPD (n=11) and age- and gender-matched controls (n=14) 
by flow cytometry. Since in the 1
st
 blood collection, none of the patients with COPD had 
started pulmonary rehabilitation, we analyzed the COPD and COPD-PR groups as a single 
group. To address the function of iNKT cells, their capacity to produce cytokines and to 
express cytotoxic markers after stimulation was also analyzed. 
 
The percentage of iNKT cells did not seem to modify in chronic obstructive 
pulmonary disease patients’ peripheral blood 
As expected, we found a high variation in the percentage of iNKT cells in the 
peripheral blood of subjects (Table 6 and Figure 16). However, no significant differences 
were observed in the percentage of iNKT cells, when patients with COPD were compared 
to age- and gender-matched controls (Figure 16). NK cell percentage was also determined 
and no significant differences were found (Table 6). 
 
46 
 
Table 6. Statistical results of T lymphocyte, iNKT cell subsets and NK cells in patients with chronic 
obstructive pulmonary disease and age- and gender-matched controls. 
 
%
a,b
 / MFI
c
 
Control 
(n=14) 
COPD 
(n=11) 
p value 
iNKT
a
 0.06±0.06 0.89±2.76 0.600
d
 
iNKT CD4
+b 
39.58±24.62 34.73±28.66 0.653
e
 
iNKT CD8
+b 
16.53±16.67 27.43±16.99 0.122
e
 
iNKT DN
b 
42.67±19.23 32.23±16.66 0.167
e
 
iNKT CD161
+b 
81.61±81.61 66.65±28.34 0.124
d
 
iNKT CD56
+b
 13.92±21.02 18.61±17.75 0.250
d
 
iNKT CD69
+c
 215.89±149.31 160.41±152.06 0.046
d
* 
CD4
+a 
64.71±10.89 63.42±8.41 0.749
e
 
CD8
+a 
30.21±9.68 29.46±7.05 0.833
e
 
NK
a
 17.41±9.43 22.36±11.37 0.246
e
 
 
a Percentage among lymphocytes; b Percentage among iNKT cells; c mean fluorescence intensity;  
d Mann-Whitney U test; e Unpaired T-test.  
COPD: Chronic Obstructive Pulmonary Disease; iNKT: invariant Natural Killer T cell; NK: Natural 
Killer cell. Data are presented as Mean values ± Standard deviation; *p <0.05. 
 
 
Figure 16. iNKT cells percentage among T lymphocytes in the peripheral blood of age- and gender-matched 
controls and patients with COPD. iNKT cells were identified in the gate of T cells (CD3
+
) as positive for 
CD1d-PBS57 tetramer, by flow cytometry. Horizontal bars represent means.  
 
 
Patients with COPD did not seem to present major alterations in iNKT cell 
subsets: only a decrease in the expression of the activation marker CD69 in iNKT cells 
It has been shown that iNKT cells are a heterogeneous population composed by 
functionally distinct subsets. The frequencies of iNKT CD8
+
, CD4
+
 and DN cells in 
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patients with COPD and controls are represented in Figure 17. Despite the absence of 
statistically significant alterations in these three iNKT cell subsets between patients with 
COPD and age- and gender-matched controls, there was a tendency for higher iNKT CD8
+
 
cells percentage in the COPD group. Conversely, iNKT DN cells in patients tended to have 
lower percentages than controls (Figure 17). 
 
 
Figure 17. Percentage of iNKT cell subsets among peripheral blood iNKT cells from age- and gender-
matched controls and patients with COPD. A, B, C – iNKT CD8+ (A) or CD4+ (B) or DN (C) cells 
percentage. 
 
As a control, we also analyzed the percentage of total CD4
+
 and CD8
+
 T cells 
(Table 6). Like for iNKT cells, no significant alterations were observed when patients with 
COPD were compared to controls (Table 6). 
The analysis of the percentage of iNKT cells expressing CD161 and CD56 did not 
present statistically significant differences (Table 6).  
CD69 is known to be constitutively expressed in iNKT cells. We analyzed the 
expression of this activation marker on iNKT cells and we found that patients with COPD 
presented a lower expression (p<0.05), as determined by, mean fluorescence intensity of 
this molecule (Figure 18).  
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Figure 18. Mean fluorescence intensity of CD69 on iNKT cells in the peripheral blood of age- and gender-
matched controls and patients with COPD. Horizontal bars represent means. Mann-Whitney U test was used 
to determine statistical significance *p<0.05 among controls and patients with COPD. 
 
Expression of cytotoxic markers on iNKT cells in patients with COPD: decrease 
in the iNKT DN cell subset expressing CD107a 
The cytotoxic capacity of iNKT cells was also inferred by the study of different 
cytotoxic markers. The expression of CD158b, CD107a and Granzyme B in total CD8
+
 T 
cells and iNKT cells was analyzed. CD8
+
 T cells did not present significant differences in 
the expression of cytotoxic markers (data not shown). As shown in Figure 19, we verified 
that the percentage of iNKT cells expressing CD158b, CD107a and Granzyme B did not 
display statistically significant differences between COPD group and age- and gender-
matched controls. Nevertheless, patients with COPD tended to have a lower percentage of 
CD107a
+
 iNKT cells than controls. In both studied groups, Granzyme B expression was 
very low (Figure 19). 
 
Figure 19. Percentage of iNKT cells expressing cytotoxic markers in the peripheral blood of age- and 
gender-matched controls and patients with COPD. A, B, C – Percentage of iNKT cells expressing CD158b 
(A) or CD107a (B) or Granzyme B (C). Horizontal bars represent means. 
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These cytotoxic markers were also analyzed in iNKT CD4/CD8/DN cell subsets. 
Only in the iNKT DN cell subset there was a statistically significant decrease (p<0.05) in 
the percentage of cells expressing CD107a in patients with COPD when compared to 
controls (Figure 20).  
 
 
Figure 20. Percentage of iNKT cell subset expressing CD107a in the peripheral blood of age- and gender-
matched controls and patients with COPD. A, B, C – Percentage of iNKT CD8+ (A) or CD4+ (B) or DN (C) 
cells expressing CD107a. Horizontal bars represent means. Unpaired T-test was used to determine statistical 
significance *p<0.05 among controls and patients with COPD. 
 
We also verified the expression of CD158b in NK cells, but no significant 
alterations were found between patients and healthy controls (data not shown). 
 
No significant alterations were observed in cytokine production by iNKT cells in 
patients with COPD 
Due to the low number of iNKT cells in the peripheral blood, testing cytokine 
production ex vivo would require a large amount of blood. Thereby, iNKT cells from 
PBMCs were expanded, by culturing them for 11-14 days in the presence of α-GalCer and 
IL-2. The expanded cells were then stimulated with PMA/Ionomycin in the presence of 
Brefeldin A and the amount of IFN-γ or/and IL-4 producing cells was determined by flow 
cytometry (Figure 21). 
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Figure 21. Gating strategy used to determine the percentage of iNKT cells producing cytokines after 
stimulation with PMA/Ionomycin in the presence of Brefeldin A. 
 
 Patients with COPD presented no significant alterations in the percentage of iNKT 
cells producing cytokines, although a tendency for a reduction of IL-4 production is 
present (Figure 22). 
%
 c
y
t
o
k
in
e
 i
N
K
T
 c
e
ll
s
I L -4 + I F N -+ I L -4 +  I F N -+ I L -4 -  I F N - -
0
2 0
4 0
6 0
8 0
C O P D
C o n tr o l
 
Figure 22. Response of iNKT cells from patients with COPD to PMA/Ionomycin/Brefeldin A stimulation. 
Expanded iNKT cells were stimulated with PMA+Ionomycin in the presence of Brefeldin A for 5h. The 
percentage of cells producing IL-4 or/and IFN-γ in age- and gender-matched controls and patients with 
COPD was determined by flow cytometry.  Experiments performed with thawed PBMCs. Results are 
represented as Mean values ± Standard deviation of 6 patients with COPD and 10 age- and gender-matched 
controls.  
 
No significant alterations were observed in the cytotoxicity of iNKT cells after 
stimulation in patients with COPD 
An important focus of this study was iNKT cell cytotoxicity. Since Granzyme B is 
known to be upregulated after stimulation, the percentage of Granzyme B in expanded and 
stimulated iNKT cells was determined by flow cytometry. We found no significant 
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alterations in percentage of iNKT cells expressing Granzyme B, however, a tendency for a 
reduction was observed in patients with COPD (Figure 23). 
 
 
Figure 23. Response of iNKT cells from patients with COPD to PMA/Ionomycin/Brefeldin A stimulation. 
Expanded iNKT cells were stimulated with PMA+Ionomycin in the presence of Brefeldin A for 5h. 
Percentage of iNKT cells expressing Granzyme B. Experiments performed with thawed PBMCs. Horizontal 
bars represent means. 
 
4.3.2. Effect of pulmonary rehabilitation on iNKT cells in patients with 
chronic obstructive pulmonary disease  
To determine the effect of pulmonary rehabilitation of patients with COPD in iNKT 
cells, two analyses were conducted: baseline/pre (1
st
 blood collection) and post-pulmonary 
rehabilitation (2
nd
 blood collection). Three distinct groups of participants were defined, i.e., 
patients with COPD who performed pulmonary rehabilitation (COPD-PR), patients with 
COPD that were never treated with pulmonary rehabilitation (COPD) and age- and gender-
matched controls. We had one dropout from the 1
st
 to the 2
nd
 blood collections (the same 
patient with COPD who did not complete the clinical assessments), thus a total of twenty-
four participants completed the study. 
 
The percentage of iNKT cells was not altered in the peripheral blood of patients 
with chronic obstructive pulmonary disease after the pulmonary rehabilitation 
To access the effect of pulmonary rehabilitation on the iNKT cells of patients with 
COPD, we compared the percentage of iNKT cells between COPD and COPD-PR groups 
in post-pulmonary rehabilitation (Figure 24A). No statistically significant alterations were 
observed between groups. In addition we compared the percentage of iNKT cells within 
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the COPD-PR group before and after pulmonary rehabilitation. Similarly, no significant 
differences were observed (Figure 24B).  
 
Figure 24. Effect of pulmonary rehabilitation on the percentage of iNKT cells among T lymphocytes in the 
peripheral blood. A – iNKT cells percentage in COPD and COPD-PR groups in the post analysis; B – iNKT 
cell percentage in patients from the COPD-PR group, before (pre) and after (post) performing pulmonary 
rehabilitation. iNKT cells were identified in the gate of T cells (CD3
+
) as positive for CD1d-PBS57 tetramer, 
by flow cytometry. Horizontal bars represent means.  
 
 
No significant alterations were observed in the iNKT cell subsets in patients with 
COPD after the pulmonary rehabilitation 
We also analyzed the effect of pulmonary rehabilitation in iNKT cell subsets. An 
absence of significant alterations in the percentage of iNKT cell subsets between the two 
groups was observed, as well as between pre and post-pulmonary rehabilitation in COPD-
PR group (Figure 25). However, patients in COPD-PR group presented a tendency for a 
reduction in the percentage of iNKT CD8
+
 cells (Figure 25D), which did not reach 
statistical significance.  
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Figure 25. Effect of pulmonary rehabilitation on the percentage of iNKT cell subsets in the peripheral blood. 
A, B, C – Percentage of iNKT CD8+ (A), or CD4+ (B), or DN (C) cells in COPD and COPD-PR groups in 
the post analysis; D, E, F – Percentage of iNKT CD8+ (D), or CD4+ (E), or DN (F) cells in patients of the 
COPD-PR group, before (pre) and after (post) performing pulmonary rehabilitation. Horizontal bars represent 
means.  
 
Similarly, no statistically significant changes were observed in the percentage of 
iNKT cells expressing CD56 and CD161, between COPD and COPD-PR groups (Figure 
26A and B), neither before nor after pulmonary rehabilitation of the COPD-PR group 
(Figure 26C and D). Nevertheless, patients who performed pulmonary rehabilitation tended 
to have higher a percentage of iNKT CD161
+
 cells and a lower percentage of iNKT CD56
+
 
cells (Figure 26C and D, respectively). 
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Figure 26. Effect of pulmonary rehabilitation on the percentage of CD161
+
 and CD56
+
 iNKT cells in the 
peripheral blood. A, B – Percentage of iNKT cells expressing CD161 (A) or CD56 (B) in COPD and COPD-
PR groups in the post analysis; C, D – Percentage of iNKT cells expressing CD161 (C) or CD56 (D) in 
COPD-PR group, before (pre) and after (post) performing pulmonary rehabilitation. Horizontal bars represent 
means. 
 
Pulmonary rehabilitation did not seem to affect the CD69 decrease observed in 
patients with COPD  
Since CD69 expression was decreased in patients with COPD, we wanted to see if 
pulmonary rehabilitation could improve this defect. We found no statistically significant 
differences between patients from the COPD-PR group and the COPD group (Figure 27A), 
neither between pre and post-pulmonary rehabilitation in patients from the COPD-PR 
group (Figure 27B). 
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Figure 27. Effect of pulmonary rehabilitation on the mean fluorescence intensity of CD69 on iNKT cells in 
the peripheral blood. A – Mean fluorescence intensity of iNKT cells expressing CD69 in COPD and COPD-
PR groups in the post analysis; B – Mean fluorescence intensity of iNKT cells expressing CD69 in COPD-
PR group, before (pre) and after (post) performing pulmonary rehabilitation. Horizontal bars represent 
means.  
 
Expression of cytotoxic markers on iNKT cells in patients with COPD after 
pulmonary rehabilitation: increase in the percentage of iNKT cells expressing Granzyme B 
but did not seem to affect CD107a
+
 iNKT DN decrease 
The impact of pulmonary rehabilitation in the expression of cytotoxic markers 
expressed by iNKT cells was also analyzed. As shown in Figure 28A and C, no statistically 
significant changes were found in percentage of iNKT cells expressing CD158b
 
between 
COPD and COPD-PR groups, neither between pre and post-pulmonary rehabilitation in the 
COPD-PR group.  
Regarding the percentage of iNKT cells expressing Granzyme B, a statistically 
significant increase (p<0.05) was observed in patients of the COPD-PR group in 
comparison with patients with COPD who never underwent pulmonary rehabilitation 
(Figure 28B). This was also a tendency when the same patients were analyzed before and 
after they had performed pulmonary rehabilitation (Figure 28D). 
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Figure 28. Effect of pulmonary rehabilitation on the percentage of iNKT cells cytotoxic markers in the 
peripheral blood. A, B – Percentage of iNKT cells expressing CD158b (A) or Granzyme B (B) in COPD and 
COPD-PR groups in the post analysis; C, D – Percentage of  iNKT cells expressing CD158b (C) or 
Granzyme B (D) in the COPD-PR group, before (pre) and after (post) performing pulmonary rehabilitation. 
Horizontal bars represent means. Mann-Whitney U test was used to determine statistical significance 
*p<0.05 among COPD and COPD-PR groups. 
 
When we analyzed CD107a expression in the baseline/pre, we found a tendency for 
a decrease of CD107a expression in iNKT cells, which was significant for the iNKT DN 
subset, in patients with COPD. When we compared the COPD and COPD-PR groups in the 
post-pulmonary rehabilitation, no significant alterations were observed in total iNKT cells 
(Figure 29A). In relation to percentage of iNKT cells expressing CD107a in COPD-PR 
group before and after pulmonary rehabilitation, no significant changes were detected, but 
we could observe that 3 out of the 4 patients of this group had a tendency to increase 
CD107a expression in iNKT cells (Figure 29B), after pulmonary rehabilitation. 
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Figure 29. Effect of pulmonary rehabilitation on the percentage of iNKT cells expressing CD107a in the 
peripheral blood. A – Percentage of iNKT cells expressing CD107a in the COPD and COPD-PR groups in 
the post analysis; B – Percentage of iNKT cells expressing CD107a in patients from the COPD-PR group, 
before (pre) and after (post) performing pulmonary rehabilitation. Horizontal bars represent means.  
 
The analysis of cytotoxic markers in iNKT cell CD4/CD8/DN subsets did not 
reveal significant alterations in patients with COPD after pulmonary rehabilitation (data 
not shown).  
 
4.4.  Correlations between clinical variables for chronic obstructive 
pulmonary disease and immunological variables 
For this section we used the clinical and immunological data obtained from the 
baseline/pre, and thus COPD and COPD-PR groups were treated as single group of 
patients with COPD (n=11). The control group was composed by 14 subjects. Tables S1 to 
S4 in appendix III have the p values of performed correlations.  
 
The percentage of NK cells was positively correlated with MIP in patients with COPD 
We started by performing a correlation analysis between lymphocyte subsets (NK, 
iNKT, CD4
+
 and CD8
+
 T cells) and clinical variables. The percentage of CD4
+
 and CD8
+
 
T lymphocytes and of iNKT cells did not display any correlation with studied clinical 
variables in patients with COPD (Appendix III – Table S2). However, there was a 
moderate positive correlation (rs=0.609, p=0.047) between NK cells and maximal 
inspiratory pressure (MIP) in patients with COPD (Figure 30B), which did not occur in 
healthy controls (Figure 30A and appendix III – Table S1). 
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Figure 30. Correlation between percentage of NK cells and values (cmH2O) of MIP in age- and gender-
matched controls (A) and patients with COPD (B). rs: Spearman’s rank correlation coefficient. Correlation is 
significant when p<0.05 (two-tailed). 
  
iNKT DN cells was correlated with MIP and MEP in patients with COPD  
We have also performed a correlation analysis between the percentage of iNKT cell 
subsets and clinical parameters. In patients with COPD, the percentage of iNKT DN cells 
displayed negative correlations with the measures of respiratory muscle strength: a 
moderate negative correlation (rs=-0.691, p=0.019) between iNKT DN cells and maximal 
inspiratory pressure (MIP, Figure 31B), and a high negative correlation (rs=-0.770, 
p=0.006) between iNKT DN cells and maximal expiratory pressure (MEP, Figure 31D). 
No significant correlation was found in age- and gender-matched controls for these 
parameters (Figure 31A and C, and appendix III – Table S1). 
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Figure 31. Correlation between percentage of iNKT DN cells and values (cmH2O) of respiratory muscle 
strength in age- and gender-matched controls and patients with COPD. A, B – Correlation between 
percentage of iNKT DN cells and values (cmH2O) of MIP in age- and gender-matched controls (A) and 
patients with COPD (B); C, D – Correlation between percentage of iNKT DN cells and values (cmH2O) of 
MEP in age- and gender-matched controls (C) and patients with COPD (D). rs: Spearman’s rank correlation 
coefficient. B – Correlation is significant when p<0.05 (two-tailed); D – Correlation is significant at the 0.01 
level (two-tailed). 
 
The activation marker CD69 was negatively correlated with FEV1 
CD69 expression on iNKT cells showed a moderate negative correlation (rs=-0.699, 
p=0.017) with predicted forced expiratory volume in one second (FEV1) in patients with 
COPD (Figure 32B). Age- and gender-matched controls did not show a significant 
correlation between these two parameters (Figure 32A and appendix III - Table S1). 
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Figure 32. Correlation between mean fluorescence intensity of CD69 in iNKT cells and the percentage of 
predicted FEV1 in age- and gender-matched controls (A) and patients with COPD (B). rs: Spearman’s rank 
correlation coefficient. Correlation is significant when p<0.05 (two-tailed). 
 
Cytotoxic markers displayed correlations with different clinical variables in patients 
with COPD  
We performed an extensive correlation analysis between clinical variables and 
cytotoxic markers (Tables S3 and S4 in appendix III).  
The percentage of CD8
+
 T cells expressing CD158b displayed a high negative 
correlation (rs=-0.727, p=0.011) with MIP in patients with COPD (Figure 33B), but not in 
controls (Figure 33A, Appendix III – Table S3). 
 
 
Figure 33. Correlation between percentage of CD8
+
 T cells expressing CD158b and values (cmH2O) of MIP 
in age- and gender-matched controls (A) and patients with COPD (B). rs: Spearman’s rank correlation 
coefficient. Correlation is significant when p<0.05 (two-tailed). 
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Patients with COPD also had a high positive correlation (rs=0.788, p=0.004) between 
the percentage of iNKT cells expressing CD158b and the percentage of predicted forced 
vital capacity (FVC, Figure 34B). This correlation was not present in controls (Figure 34A 
and appendix III – Table S3).  
 
 
Figure 34. Correlation between percentage of iNKT cells expressing CD158b and percentage of predicted 
FVC in age- and gender-matched controls (A) and patients with COPD (B). rs: Spearman’s rank correlation 
coefficient. Correlation is significant at the 0.01 level (two-tailed). 
 
Furthermore, iNKT CD8
+
 cells expressing CD158b displayed a moderate negative 
correlation (rs=-0.671, p=0.024) with ratio of forced expiratory volume in one second and 
forced vital capacity (FEV1/FVC) in patients with COPD (Figure 35B). Once again, age- 
and gender-matched controls did not present significant correlations with these parameters 
(Figure 35A and appendix III – Table S3). 
 
 
Figure 35. Correlation between percentage of iNKT CD8
+
 cells expressing CD158b and FEV1/FVC ratio in 
age- and gender-matched controls (A) and patients with COPD (B). rs: Spearman’s rank correlation 
coefficient. Correlation is significant when p<0.05 (two-tailed). 
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Conversely, a moderate negative correlation (rs=-0.694, p=0.018) between the 
percentage of CD8
+
 T cells expressing Granzyme B and the percentage of predicted FEV1 
was present in patients with COPD (Figure 36B), but not in control subjects (Figure 36A, 
appendix III – Table S3). 
 
 
Figure 36. Correlation between percentage of CD8
+
 T cells expressing Granzyme B and percentage of 
predicted FEV1 in age- and gender-matched controls (A) and patients with COPD (B). rs: Spearman’s rank 
correlation coefficient. Correlation is significant when p<0.05 (two-tailed). 
 
A correlation between FEV1/FVC ratio and the percentage of iNKT cells expressing 
Granzyme B was also established in patients with COPD (Figure 37B). This was a high 
negative correlation (rs=-0.730, p=0.011). No significant correlation was shown in age- and 
gender-matched controls (Figure 37A and appendix III – Table S3). 
 
 
Figure 37. Correlation between percentage of iNKT cells expressing Granzyme B
 
and FEV1/FVC ratio in 
age- and gender-matched controls (A) and patients with COPD (B). rs: Spearman’s rank correlation 
coefficient. Correlation is significant when p<0.05 (two-tailed). 
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 Interestingly, the percentage of iNKT DN cells expressing Granzyme B was also 
negatively correlated (rs=-0.682, p=0.021) with this parameter in patients with COPD, 
although at a moderate level (Figure 38B). In controls this correlation was not significant 
(Figure 38A and appendix III – Table S3).  
 
 
Figure 38. Correlation between the percentage of iNKT DN cells expressing Granzyme B and FEV1/FVC 
ratio in age- and gender-matched controls (A) and patients with COPD (B). rs: Spearman’s rank correlation 
coefficient. Correlation is significant when p<0.05 (two-tailed). 
 
 
 
 
 
 
 
  
 
 
 
 
 
5. Discussion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
67 
 
5.1.  Effect of pulmonary rehabilitation on clinical measures for chronic 
obstructive pulmonary disease 
In patients with COPD, pulmonary rehabilitation has clearly demonstrated to reduce 
symptoms (e.g., dyspnea), improve muscle force and activity, promote autonomy and 
participation in daily activities, improve health-related quality of life and reduce healthcare 
utilization [42], [43], [133]. In this study, only COPD Assessment Test (CAT) presented 
significant changes between groups, i.e., in the age- and gender-matched controls this 
clinical measure did not present differences between the 1
st
 and the 2
nd
 clinical assessment, 
while patients with COPD with and without pulmonary rehabilitation presented different 
values over time.  This result revealed that healthy subjects presented a better quality of 
life than the patients, as predicted. No other significant changes were observed. The 
absence of significant improvements in patients who underwent pulmonary rehabilitation 
may be justified by the fact that only four patients adhered to this treatment, and thus a 
small number of subjects was analyzed. 
 
5.2.  Analysis of iNKT cells in chronic obstructive pulmonary disease 
In this study, no differences were found in iNKT cell percentage in the peripheral 
blood of healthy controls in comparison with patients with COPD. As expected, we found 
a high variation in the percentage of iNKT cells in the peripheral blood of both groups. 
Previous studies have described conflicting results.  A previous study (nCOPD=10) found a 
decreased frequency of iNKT cells in peripheral blood of patients with stable COPD when 
they stained the cells with 6B11 monoclonal antibody, however, when the iNKT cells were 
stained with α-GalCer-loaded CD1d-tetramer, no significant alterations were found 
between groups, according to our results [113]. Conersely, an increase of iNKT cell 
frequency in the peripheral blood of patients with COPD was observed (nCOPD=28) [114]. 
In another study, frequency of iNKT cells were analyzed in induced sputum, airway biopsy 
and bronchoalveolar lavage, but no significant differences were found between controls 
and patients with COPD (nCOPD=5) [117].  
We found no significant differences in the percentage of NK cells when patients with 
COPD were compared to age- and gender-matched controls. This is in accordance with 
two previous studies (nCOPD=56) [134]; (nCOPD=30 ex-smokers; nCOPD=41 current smokers) 
[103], but contrary to what was observed in other study, which described a decrease in 
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relative number of NK cells in the peripheral blood (nCOPD=11) [99]. In induced sputum 
and in airways of patients with COPD, the percentage of NK cells are increased 
(nCOPD=11) [96]; (nCOPD=41) [103]. No difference was found in the number of NK cells in 
lung parenchyma (nCOPD=6 non-smokers; nCOPD=5 smokers without parenchymal 
destruction; nCOPD=10 smokers with parenchymal destruction) [20]. 
Regarding the iNKT cell subsets, patients with COPD did not present significant 
differences in any subset in comparison with healthy subjects. Studies of the iNKT cell 
subsets in COPD are scarce. When the researchers studied the CD4
+
 iNKT cells stained 
with α-GalCer-loaded CD1d-tetramer no significant differences in the frequencies between 
patients with COPD and healthy control subjects were observed, in accordance to our 
results [113].  
As a control, we also analyzed the percentage of total CD4
+
 and CD8
+
 T cells and 
likewise no significant alterations were observed when patients with COPD were 
compared to controls. In accordance with our results, other study also did not obtain 
significant differences in the number of CD8
+
 T cells in the peripheral blood of patients 
with COPD comparing with controls, while the number of CD4
+
 T cells was reduced in 
patients [3]. In the airways and in lung parenchyma of patients with COPD, both CD4
+
 and 
CD8
+
 T cells are increased [12]. Additionally, the percentage of CD8
+
 T cells  further 
increases with COPD progression [17]. Increased CD8
+
 T cells were also observed in 
repeatedly α-GalCer administered mice, which produce similar pathological hallmarks of 
COPD [115]. 
Importantly, a decrease in the expression of CD69 in patients with COPD was found. 
CD69 is a surface marker of early stage lymphocyte activation [135]. Our results can 
indicate that COPD interferes in some way with the early activation of iNKT cells. A study 
which investigated the potential role of iNKT cells in a mice model of chronic exposure to 
cigarette smoke mimicking COPD symptoms, and in an acute model of lipid peroxidation 
using cumen hydroperoxide (CHP) as the trigger, concluded that exposure to CHP led to 
an enhanced CD69 expression on iNKT cells [114].  
In this study, we also analyzed for the first time the expression of cytotoxic markers 
(CD158b, CD107a and Granzyme B) in iNKT cells, in the context of COPD. It is know 
that CD158b is a inhibitory receptor that is altered in NK cells in patients with COPD [3]. 
However, we did not found alterations in this marker in patients with COPD. Granzyme B 
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is the most common granzyme and an effector of cytotoxicity, activating pro-caspases, thus 
inducing apoptosis initiating [97]. It is also known that Granzyme B is altered in CD8
+
 T 
cells and NK cells in patients with COPD [99], [102], [103]. In this study, we found no 
alterations in Granzyme B expression in iNKT cells at the basal level. However, upon 
stimulation, a tendency for a decrease in the expression of Granzyme B by iNKT cells was 
found. This might indicate a reduction in the cytotoxic capacity of iNKT cells from the 
peripheral blood of patients with COPD.  Finally, CD107a is a degranulation marker, 
which is upregulated in iNKT cells after stimulation and it is defective in cells that are 
exposed to cigarette smoke [107]–[109]. We found a tendency for a decrease in expression 
of CD107a in total iNKT cells from patients with COPD, which did not reach statistical 
significance. Interestingly, a significant reduction in CD107a expression was observed in 
iNKT DN cells. This is accordance with what was expected, since COPD is mainly caused 
by cigarette smoke. It may also indicate that iNKT cells from patients with COPD are less 
prone to release cytotoxic granules. 
It is known that cytokines play a key role in orchestrating the chronic inflammation of 
COPD by recruiting, activating, and promoting the survival of multiple inflammatory cells 
in the respiratory tract [1]. In this study, we demonstrated that, upon stimulation, cytokine 
production (IL-4 and IFN-γ) by iNKT cells from peripheral blood is not altered in COPD. 
To our knowledge, this is the first study analyzing the production of cytokines by iNKT 
cells in COPD, however it was previously demonstrated that the production of IFN-γ and 
IL-4 by CD8
+
 T cells is increased in bronchoalveolar lavage [136]. Likewise, the 
percentage of IFN-γ+ CD8+ T cells in peripheral blood is increased in stable patients with 
COPD when compared to healthy never-smoking controls [137].  
Overall, we performed an extensive analysis of iNKT cells from the peripheral blood of 
patients with COPD. We found that these cells seem to be less activated, as determined by 
CD69 expression. Furthermore, our results suggest that iNKT cells from patients with 
COPD may have a decrease in cytotoxic capacity. It would be important to increase the 
number of patients analyzed to take definitive conclusions. 
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5.3.  Effect of pulmonary rehabilitation on iNKT cells in patients with 
chronic obstructive pulmonary disease  
This part of the study was limited by the low number of patients that performed 
pulmonary rehabilitation (n=4). We did not found significant differences in the percentage 
of iNKT cells, neither in their subsets after pulmonary rehabilitation in patients of the 
COPD-PR group and in comparison with patients with COPD who never undergone this 
treatment. Furthermore, the reduction in CD69 expression observed in patients with COPD 
did not seem to be altered by pulmonary rehabilitation. On the contrary, we found a 
significant increase in the percentage of iNKT cells expressing Granzyme B in patients of 
the COPD-PR group in comparison with patients with COPD who never performed 
pulmonary rehabilitation, and this was also a tendency when the same patients were 
analyzed before and after they had performed pulmonary rehabilitation. Although 
pulmonary rehabilitation did not seem to affect the decrease in CD107a
+
 iNKT DN cells, 3 
out of the 4 patients of the COPD-PR group had a tendency to increase CD107a expression 
in iNKT cells after the treatment, which can indicate that pulmonary rehabilitation can 
improve this parameter. These results suggest that pulmonary rehabilitation may contribute 
to the increase in iNKT cell cytotoxicity and may have a role in improving the cytotoxic 
defect. It would be important to increase the number of patients analyzed, who underwent 
the pulmonary rehabilitation to improve the conclusions. 
 
5.4.  Correlations between clinical variables for chronic obstructive 
pulmonary disease and immunological variables 
In our investigation, we found a positive correlation between NK cells and maximal 
inspiratory pressure (MIP) in patients with COPD, indicating that these two variables are 
directly proportional. Furthermore, iNKT DN cells displayed negative correlations with the 
measures of respiratory muscle strength: MIP and maximal expiratory pressure (MEP). 
CD69 expression on iNKT cells showed a negative correlation with predicted forced 
expiratory volume in one second (FEV1) in patients with COPD. So, expression of CD69 
in iNKT cells seems to increase with pulmonary function decline. This was not expected, 
since we found that patients with COPD had a decrease in CD69 expression in iNKT cells. 
Regarding to cytotoxic markers, a negative correlation between the percentage of CD8
+
 
T cells expressing CD158b and MIP was observed in patients, indicating that these two 
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variables are inversely proportional. We also found a positive correlation between the 
percentage of iNKT cells expressing CD158b and the percentage of predicted forced vital 
capacity (FVC) in patients with COPD. This might indicate that CD158b expression is 
associated with an improvement in the health condition of the patient. Furthermore, iNKT 
CD8
+ 
cells expressing CD158b displayed a moderate negative correlation with FEV1/FVC 
ratio in patients with COPD. It was possible verified that when this inhibitory receptor 
increases in iNKT CD8
+
 cells, the pulmonary function gets worse, indicating that the 
frequency of CD158b
+
 iNKT CD8
+
 cells reflects the severity of COPD to a certain extent. 
A negative correlation between the percentage of CD8
+
 T cells expressing Granzyme B in 
the peripheral blood and the percentage of predicted FEV1 was found in patients with 
COPD. This is in accordance with a previous investigation, which also found a negative 
correlation between CD8
+
 T cells expressing Granzyme B and predicted FEV1 in the lungs, 
demonstrating that CD8
+
 T cells display increased transcripts for Granzyme B with 
worsening pulmonary function [138]. Lastly, the percentage of total iNKT and of DN 
iNKT cells expressing Granzyme B displayed a negative correlation with FEV1/FVC ratio 
in patients with COPD. A significant correlation between Granzyme B expression in BAL-
derived T-cells and apoptosis of bronchial epithelial cells was found [102]. The idea that 
apoptosis of lung structural cells might contribute to parenchymal destruction has gained 
increasing support from basic and clinical data [139], [140].  
Since the immunological investigations addressed to the chronic obstructive pulmonary 
disease are very few, these new data about the correlations of clinical health and 
lymphocytes can promote new studies in this disease, including more patients. 
We had some limitations in the performance of this project, such as: only a few patients 
with the inclusion criteria and that accepted participate in the study; the poor adherence by 
the patients with COPD to the pulmonary rehabilitation; and the freeze of some blood 
samples, like referred in the part of the materials and methods. 
Our findings open paths to new investigations about the cytotoxic markers role in 
COPD, as well as the effect of pulmonary rehabilitation on the immune system, to enhance 
our knowledge on the pathology and pathogenesis of this chronic disease which is a major 
cause of chronic morbidity and mortality throughout the world. 
  
 
 
 
 
 
6. Conclusion 
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We analyzed the iNKT cells in patients with COPD. No alteration in percentage of 
iNKT cells, their subsets (CD4/CD8/DN) and cytokine production (IL-4 and IFN-γ) in the 
peripheral blood of patients with COPD was found in comparison with age- and gender-
matched controls. Importantly, iNKT cells seem to be less activated, as determined by 
reduction of CD69 expression. Here we analyzed for the first time the expression of 
cytotoxic markers (CD158b, CD107a and Granzyme B) in iNKT cells and their subsets, in 
the context of COPD. Our results suggest that iNKT cells from patients with COPD may 
have a decrease in cytotoxic capacity, by a tendency for a decrease in the percentage of 
Granzyme B
+
 iNKT cells upon stimulation, further a tendency for a decrease in expression 
of CD107a in total iNKT cells, followed by a significant reduction in CD107a expression 
in iNKT DN cells. It would be important to increase the number of patients analyzed to 
strengthen our conclusions. It would also be interesting analyze the iNKT cells in the 
airways, induced sputum or lung tissue of patients with COPD, because they are the source 
of inflammation of this chronic disease. 
Relatively to the effect of pulmonary rehabilitation on iNKT cells in patients with 
COPD, no differences were observed in the percentage of iNKT cells, neither in their 
subsets after pulmonary rehabilitation. The reduction in CD69 expression observed in 
patients with COPD did not seem to be altered. Our results about iNKT cells expressing 
Granzyme B and CD107a suggest that pulmonary rehabilitation may contribute to the 
increase in iNKT cell cytotoxicity and may have a role in improving the cytotoxic defect. It 
would be necessary to increase the number of patients analyzed, who underwent 
pulmonary rehabilitation to be able to conclude about the effects of such intervention on 
immunological state.  
An extensive correlation analysis between clinical measures for COPD and 
immunological measures it was performed for the first time. It was found positive 
correlations in patients with COPD between percentage of NK cells and MIP, and iNKT 
cells expressing CD158b and the percentage of predicted FVC. This might indicate that 
these cells are associated with an improvement in the health condition of the patient. 
Several negative correlations were also found between percentage of iNKT DN cells and 
measures of respiratory muscle strength (MIP and MEP), iNKT cells expressing CD69 and 
FEV1, CD8
+
 T cells expressing CD158b and MIP, iNKT CD8
+
 cells expressing CD158b 
and FEV1/FVC ratio, CD8
+
 T cells expressing Granzyme B and FEV1, and iNKT and of 
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DN iNKT cells expressing Granzyme B and FEV1/FVC ratio. This might indicate that 
these cells are associated with worsening of COPD. These correlations are the beginning of 
in-deep studies about this chronic disease, promoting further investigations and maybe new 
treatments. 
The studies about iNKT cells addressed to the COPD are scarce and those that exist 
have described conflicting results. So, our investigation open paths to new studies about 
the role of iNKT cells, their cytotoxicity and cytokine production in the pathology and 
pathogenesis of COPD, as well as, the effect of pulmonary rehabilitation in immune 
system of these patients. This investigation work is a comprehensive study about COPD, 
enriched by the combination of clinical and laboratory data collection, allowing me to 
acquire knowledge in the field of pulmonary physiotherapy and immunology. 
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CONSELHO DE ÉTICA 
Parecer nº: 10/2015. 
Requerente: Doutora Maria de Fátima Macedo. 
Título do Projeto: “Efeitos da reabilitação respiratória nos linfócitos iNKT em 
pessoas com doença pulmonar obstrutiva crónica”. 
Orientadoras: Doutora Maria de Fátima Macedo (DCM) e Doutora Alda Marques 
(ESSUA). 
Equipa de Investigação: Doutora Maria de Fátima Macedo (DCM), Doutora Alda 
Marques (ESSUA) e Tânia Marante (Estudante de Mestrado). 
Relator: Doutor Armando J. Pinho. 
Relatores Adjuntos: António J. A. Nogueira, António Rocha Andrade, Jorge 
Carvalho Arroteia, Paula Cristina M. S. Pereira. 
 
I. Relatório 
 
O processo encontra-se devidamente instruído contendo elementos essenciais 
relativos a: 
 Caracterização do projeto; 
 Equipa de investigação; 
 Bibliografia; 
 Apêndices: 
1. Declaração de apoio do Diretor do Departamento de Ciência Médicas (DCM) da 
Universidade de Aveiro e Diretor do iBiMED; 
2. Declaração de apoio do Diretor do Instituto de Biologia Molecular e Celular - 
IBMC; 
3. Instrumento de recolha de dados; 
4. Folhas de informação ao participante; 
5. Formulário de consentimento informado. 
 
II. Parecer 
A. Fundamentação: 
 
1. A proposta relativa ao projeto apresenta-se devidamente fundamentada, sendo 
inteligível e exaustiva no que respeita aos seus objetivos, metodologia, indicação de 
estudos semelhantes e bibliografia. 
2. A amostra está bem definida e os procedimentos a seguir, nomeadamente no que 
respeita às exigências científicas dos instrumentos de avaliação, procedimentos de 
medida e tratamento de resultados estão desenvolvidos. 
3. Os riscos associados ao desenvolvimento do projeto estão considerados. 
4. De acordo com acima referido, a proposta respeita os princípios de ética neste 
tipo de investigação na medida em que: 
4.1. O estudo salvaguarda o consentimento informado dos participantes, com pelo 
menos 40 anos de idade e anteriormente à recolha de dados; 
4.2. O estudo salvaguarda a participação voluntária da participação; 
4.3. O estudo é devidamente acompanhado pela equipa de investigação; 
4.4. Os riscos associados à participação no estudo não são superiores aos riscos 
associados a uma colheita de sangue para análises clínicas;
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4.5. Os dados recolhidos no projeto são analisados pela equipa de investigação, 
mantendo-se confidenciais e anónimos, sob a responsabilidade das coordenadoras do 
estudo; 
4.6. Os dados são armazenados por um período de cinco anos e depois destruídos. 
 
B. Sugestões de aperfeiçoamento 
Não há. 
 
C. Conclusão 
 
De acordo com o anteriormente assinalado e com os princípios seguidos pelo 
CED é emitido o seguinte parecer: 
A Comissão Permanente do Conselho de Ética, constituída pelos ora Relatores, 
após apreciação conjunta da documentação recebida e atendendo a que os 
procedimentos descritos no estudo de investigação apresentado: 
(a) asseguram a não utilização de qualquer método invasivo para além de recolhas 
de sangue idênticas à utilizada em análises clínicas de rotina; 
(b) asseguram que os participantes, com 40 ou mais anos, serão oportunamente 
informados e esclarecidos sobre as condições em que vão decorrer as observações e 
recolha de dados, de modo a ser obtido o consentimento informado; 
(c) garantem que os dados recolhidos serão tratados de maneira a permanecerem 
confidenciais e anónimos, 
Considera, por unanimidade, que merece parecer favorável a realização do projeto 
em análise. 
 
Os Relatores: 
 
 
_______________________________________ 
 
 
_______________________________________ 
 
 
 
 
 
 
 
_______________________________________ 
 
D. Decisão 
 
Submetido ao CED o parecer da sua Comissão Permanente, este Conselho, em sua 
reunião plenária de 13 de Abril de 2016, por entender que ficam salvaguardadas as 
exigências éticas e os princípios da justiça e da autonomia e bem estar dos 
participantes concorda por unanimidade com o mesmo em razão do que o ratifica e dá 
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parecer favorável à realização do projeto “Efeitos da reabilitação respiratória nos 
linfócitos iNKT em pessoas com doença pulmonar obstrutiva crónica”. 
 
Aveiro, 13 de Abril de 2016 
 
Conselho de ética e Deontologia da Universidade de Aveiro. 
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ACK lysis solution 
For a final volume of 500mL, add 4.15g of ammonium chloride (NH4Cl) and 0.5g 
of potassium bicarbonate (KHCO3) to H2O. Adjust pH to 7.2. 
 
Culture medium - RPMI 10%iFBS: 
 500mL RPMI 1640 GlutaMAX (Invitrogen); 
 5mL of non essential aminoacids (NEA, Invitrogen); 
 5mL of kanamycin (K, Invitrogen); 
 5mL of sodium pyruvate (SP, Invitrogen); 
 50mL (10%) of inactivated fetal bovine serum (iFBS, Invitrogen). 
 
Flow cytometry solution (PBS 2%FBS 1%PenStrep 0.01%NaN3) 
For a solution final volume of 500mL add 10mL of fetal bovine serum (FBS), 5mL of 
PenStrep, 0.05g of sodium azide (NaN3) and 50mL of PBS 10x to H2O. 
 
Flow cytometry solution with Saponin (PBS 2%FBS 1%PenStrep 0.01%NaN3 0.5%Saponin) 
For 100mL of solution add 0.5g of saponin to PBS 2%FBS 1%PenStrep 0.01%NaN3. 
 
PBS 10x 
For a total volume of 1000mL add 80g of sodium chloride (NaCl), 2g of potassium 
chloride (KCl), 6.09g of sodium phosphate dibasic (Na2HPO4) and 2g of potassium 
dihydrogen phosphate (KH2PO4) to H2O. Adjust pH to 7.3. 
 
PBS 1x 
For 500mL, add 50mL of PBS 10x to 450mL of H2O. 
 
PBS 1%formaldehyde 
For a final volume of 4mL add 250μL of 16%formaldehyde to 3.75mL of PBS 1x. 
 
PBS 2%formaldehyde 
For a final volume of 4mL add 500μL of 16% formaldehyde to 3.5mL of PBS 1x.
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Table S 1. Spearman’s rank correlations between clinical variables and T lymphocytes, iNKT cell subsets 
and NK cells in age- and gender-matched controls. 
 
Control 
n = 14 
CD4+ CD8+ iNKT 
iNKT 
CD161+ 
iNKT 
CD56+ 
iNKT 
CD69+ 
iNKT 
CD8+ 
iNKT 
CD4+ 
iNK
T DN 
NK 
MIP 
(cmH2O) 
  
rs -0.134 0.222 0.486 0.284 -0.327 -0.264 0.532 -0.481 0.323 0.037 
p 0.648 0.446 0.078 0.326 0.253 0.362 0.050 0.081 0.260 0.899 
MEP 
(cmH2O) 
  
rs 0.037 -0.004 0.352 0.244 -0.227 -0.214 -0.337 0.066 0.295 0.224 
p 0.899 0.988 0.217 0.400 0.436 0.463 0.239 0.823 0.306 0.441 
5TSS (s) 
  
rs -0.020 -0.029 0.035 0.169 0.253 0.306 -0.169 0.376 -0.152 0.552* 
p 0.946 0.923 0.905 0.563 0.383 0.288 0.563 0.185 0.605 0.041 
FEV1 
predicted 
(%) 
  
rs -0.257 0.314 0.180 0.002 -0.077 0.013 0.411 -0.486 0.305 -0.336 
p 0.375 0.274 0.537 0.994 0.794 0.964 0.144 0.078 0.288 0.240 
FVC 
predicted 
(%) 
  
rs -0.055 0.057 0.209 -0.026 -0.090 0.034 0.267 -0.407 0.264 -0.332 
p 0.852 0.846 0.473 0.929 0.759 0.908 0.357 0.149 0.362 0.246 
FEV1/FVC 
  
rs -0.434 0.452 -0.291 0.007 0.205 0.119 0.428 -0.178 -0.049 -0.060 
p 0.121 0.105 0.313 0.982 0.483 0.685 0.127 0.543 0.868 0.838 
COPD: Chronic Obstructive Pulmonary Disease; MIP: Maximal Inspiratory Pressure; MEP: Maximal Expiratory Pressure; 5TSS: Five 
Time Seat to Stand; FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; FEV1/FVC: Tiffeneau index; iNKT: 
invariant Natural Killer T cell; NK: Natural Killer cell; rs: Spearman’s rank correlation coefficient. 
*Correlation is significant when p<0.05 (two-tailed). 
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Table S 2. Spearman’s rank correlations between clinical variables and T lymphocytes, iNKT cell subsets 
and NK cells in patients with chronic obstructive pulmonary disease. 
 
COPD 
n = 11 
CD4+ CD8+ iNKT 
iNKT 
CD161+ 
iNKT 
CD56+ 
iNKT 
CD69+ 
iNKT 
CD8+ 
iNKT 
CD4+ 
iNKT 
DN 
NK 
MIP 
(cmH2O) 
  
rs -0.073 0.055 -0.542 -0.191 -0.209 -0.291 -0.518 0.436 -0.691* 0.609* 
p 0.832 0.873 0.085 0.574 0.537 0.385 0.102 0.180 0.019 0.047 
MEP 
(cmH2O) 
  
rs 0.055 -0.191 -0.260 -0.351 -0.214 -0.401 -0.483 0.510 -0.770** 0.515 
p 0.873 0.573 0.440 0.290 0.527 0.222 0.132 0.109 0.006 0.105 
5TSS (s) 
  
rs 0.055 -0.182 0.492 0.127 0.327 0.282 0.391 -0.527 0.318 -0.336 
p 0.873 0.593 0.124 0.709 0.326 0.401 0.235 0.096 0.340 0.312 
FEV1 
predicted 
(%) 
  
rs -0.452 0.429 -0.201 -0.283 0.119 -0.699* -0.050 0.027 0.046 0.256 
p 0.163 0.188 0.553 0.399 0.728 0.017 0.883 0.936 0.894 0.448 
FVC 
predicted 
(%) 
  
rs -0.118 0.000 0.123 0.178 0.588 -0.337 0.319 -0.474 0.068 0.342 
p 0.729 1.000 0.718 0.601 0.057 0.311 0.339 0.141 0.842 0.304 
FEV1/FVC 
  
rs -0.311 0.498 -0.540 -0.365 -0.493 -0.342 -0.489 0.534 -0.050 0.123 
p 0.353 0.119 0.086 0.269 0.123 0.303 0.127 0.090 0.883 0.718 
COPD: Chronic Obstructive Pulmonary Disease; MIP: Maximal Inspiratory Pressure; MEP: Maximal Expiratory Pressure; 5TSS: Five 
Time Seat to Stand; FEV1: Forced Expiratory Volume in one second; FVC: Forced Vital Capacity; FEV1/FVC: Tiffeneau index; iNKT: 
invariant Natural Killer T cell; NK: Natural Killer cell; rs: Spearman’s rank correlation coefficient.  
*Correlation is significant when p<0.05 (two-tailed); **Correlation is significant at the 0.01 level (two-tailed). 
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Table S 3. Spearman’s rank correlations between clinical variables and cytotoxic markers of T lymphocytes, iNKT cell subsets and NK cells in age- and gender-matched 
controls. 
COPD: Chronic Obstructive Pulmonary Disease; MIP: Maximal Inspiratory Pressure; MEP: Maximal Expiratory Pressure; 5TSS: Five Time Seat to Stand; FEV1: Forced Expiratory Volume in one second; FVC: 
Forced Vital Capacity; FEV1/FVC: Tiffeneau index; iNKT: invariant Natural Killer T cell; NK: Natural Killer cell; rs: Spearman’s rank correlation coefficient.  
*Correlation is significant when p<0.05 (two-tailed); **Correlation is significant at the 0.01 level (two-tailed). 
 
 
 
 
Control 
n = 14 
CD8 
CD158b
+
 
CD8 
CD107a
+
 
CD8 
Granzyme B
+
 
iNKT 
CD158b
+
 
iNKT 
CD107a
+
 
iNKT 
Granzyme B
+
 
iNKT CD8 
CD158b
+
 
iNKT CD8 
CD107a
+
 
iNKT CD8 
Granzyme B
+
 
iNKT CD4 
CD158b
+
 
iNKT CD4 
CD107a
+
 
iNKT CD4 
Granzyme B
+
 
iNKT DN 
CD158b
+
 
iNKT DN 
CD107a
+
 
iNKT DN 
Granzyme B
+
 
NK 
CD158b
+
 
MIP 
(cmH2O) 
  
rs 0.242 -0.147 -0.187 0.357 -0.116 0.073 0.678** 0.526 0.319 -0.007 -0.255 0.315 -0.117 -0.394 0.028 -0.191 
p 0.404 0.615 0.523 0.210 0.692 0.805 0.008 0.053 0.266 0.982 0.379 0.273 0.691 0.164 0.926 0.512 
MEP 
(cmH2O) 
  
rs -0.118 -0.183 -0.132 0.079 -0.048 0.011 0.272 0.205 0.209 -0.004 0.086 0.415 0.114 0.045 0.279 -0.117 
p 0.688 0.532 0.653 0.787 0.869 0.970 0.347 0.483 0.472 0.988 0.770 0.140 0.699 0.878 0.335 0.691 
5TSS (s) 
  
rs -0.075 0.059 0.538* -0.126 0.007 0.316 -0.174 -0.309 0.350 0.222 0.502 0.013 -0.233 -0.154 0.358 -0.466 
p 0.799 0.840 0.047 0.669 0.982 0.272 0.551 0.282 0.220 0.446 0.068 0.965 0.422 0.599 0.209 0.093 
FEV1 
predicted 
(%) 
  
rs -0.209 -0.354 0.046 -0.108 -0.160 0.055 -0.073 -0.139 -0.262 -0.222 -0.414 -0.018 -0.225 -0.317 -0.162 -0.147 
p 0.473 0.215 0.876 0.713 0.584 0.851 0.805 0.635 0.366 0.446 0.142 0.951 0.440 0.270 0.580 0.615 
FVC 
predicted 
(%) 
  
rs -0.425 -0.546* -0.132 -0.217 -0.244 0.024 -0.128 -0.212 -0.240 -0.271 -0.419 -0.010 -0.157 -0.269 -0.138 -0.042 
p 0.130 0.044 0.653 0.456 0.400 0.934 0.662 0.466 0.409 0.349 0.136 0.972 0.593 0.353 0.639 0.887 
FEV1/FVC 
  
rs 0.160 -0.018 0.254 -0.047 0.033 0.101 -0.087 -0.123 -0.346 -0.151 -0.249 0.008 -0.292 -0.121 -0.186 -0.102 
p 0.584 0.952 0.382 0.874 0.910 0.732 0.767 0.675 0.226 0.606 0.390 0.979 0.311 0.679 0.525 0.727 
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Table S 4. Spearman’s rank correlations between clinical variables and cytotoxic markers of T lymphocytes, iNKT cell subsets and NK cells in patients with chronic 
obstructive pulmonary disease. 
COPD: Chronic Obstructive Pulmonary Disease; MIP: Maximal Inspiratory Pressure; MEP: Maximal Expiratory Pressure; 5TSS: Five Time Seat to Stand; FEV1: Forced Expiratory Volume in one second; FVC: 
Forced Vital Capacity; FEV1/FVC: Tiffeneau index; iNKT: invariant Natural Killer T cell; NK: Natural Killer cell; rs: Spearman’s rank correlation coefficient.  
*Correlation is significant when p<0.05 (two-tailed); **Correlation is significant at the 0.01 level (two-tailed). 
 
  
 
COPD 
n = 11 
CD8 
CD158b
+
 
CD8 
CD107a
+
 
CD8 
Granzyme B
+
 
iNKT 
CD158b
+
 
iNKT 
CD107a
+
 
iNKT 
Granzyme B
+
 
iNKT CD8 
CD158b
+
 
iNKT CD8 
CD107a
+
 
iNKT CD8 
Granzyme B
+
 
iNKT CD4 
CD158b
+
 
iNKT CD4 
CD107a
+
 
iNKT CD4 
Granzyme B
+
 
iNKT DN 
CD158b
+
 
iNKT DN 
CD107a
+
 
iNKT DN 
Granzyme B
+
 
NK 
CD158b
+
 
MIP 
(cmH2O) 
  
rs -0.727* -0.500 -0.455 0.100 -0.173 -0.328 0.091 -0.014 -0.140 0.101 -0.055 -0.027 0.136 -0.518 -0.223 -0.118 
p 0.011 0.117 0.160 0.770 0.612 0.325 0.790 0.968 0.682 0.768 0.873 0.937 0.689 0.102 0.510 0.729 
MEP 
(cmH2O) 
  
rs -0.588 -0.260 -0.360 -0.205 -0.433 -0.247 0.164 -0.425 0.226 -0.193 -0.132 0.047 -0.419 -0.351 -0.323 0.349 
p 0.057 0.441 0.277 0.545 0.184 0.465 0.630 0.193 0.504 0.569 0.698 0.890 0.199 0.290 0.333 0.292 
5TSS (s) 
  
rs 0.355 0.127 0.573 0.118 0.382 0.501 0.427 0.278 0.461 -0.275 -0.528 0.067 -0.091 0.236 0.590 -0.036 
p 0.285 0.709 0.066 0.729 0.247 0.116 0.190 0.408 0.154 0.413 0.095 0.844 0.790 0.484 0.056 0.915 
FEV1 
predicted 
(%) 
  
rs 0.155 0.356 -0.694* 0.393 -0.224 -0.526 -0.201 -0.327 -0.493 0.553 0.339 -0.278 0.224 -0.142 -0.212 -0.185 
p 0.649 0.282 0.018 0.232 0.508 0.096 0.554 0.326 0.123 0.078 0.308 0.408 0.508 0.678 0.532 0.585 
FVC 
predicted 
(%) 
  
rs 0.150 -0.114 -0.342 0.788** 0.278 0.082 0.319 -0.009 -0.277 0.570 0.288 0.318 0.601 -0.123 0.487 -0.066 
p 0.659 0.739 0.304 0.004 0.408 0.810 0.339 0.979 0.409 0.067 0.391 0.341 0.050 0.719 0.129 0.847 
FEV1/FVC 
  
rs -0.091 0.192 -0.530 -0.146 -0.374 -0.730* -0.671* -0.101 -0.516 0.134 0.300 -0.440 0.105 -0.187 -0.682* -0.359 
p 0.789 0.572 0.094 0.668 0.257 0.011 0.024 0.768 0.104 0.695 0.370 0.175 0.759 0.581 0.021 0.278 
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Folha de informação ao participante 
O Sr./Sra. está a ser convidado/a para participar no estudo de investigação clínica 
intitulado: “Efeitos da Reabilitação Respiratória nos Linfócitos iNKT em pessoas com 
Doença Pulmonar Obstrutiva Crónica”. Mas, antes de decidir, é importante que 
compreenda porque é que a investigação está a ser realizada e o que é que a 
mesma envolve. Por favor, leia a informação com atenção e discuta a sua 
participação com outros, se assim o entender. Se houver algo que não esteja claro 
para si ou necessitar de informação adicional, por favor contacte os investigadores 
(contactos no final deste documento). Use o tempo que precisar para decidir se 
deseja ou não participar. Muito obrigado desde já por ler a informação. 
Muito obrigado desde já por ler a informação. 
Qual é o propósito do estudo? 
Este estudo visa contribuir para a compreensão da forma como a reabilitação respiratória 
melhora a condição clinica do paciente com a Doença Pulmonar Obstrutiva Crónica, 
através do estudo de um determinado tipo de células do sistema imunitário, designadas 
Linfócitos iNKT. A DPOC é uma condição de saúde que se caracteriza por uma limitação 
do débito aéreo, geralmente progressiva e com reduzida reversibilidade. A sua origem 
está normalmente associada a uma resposta inflamatória anómala dos pulmões, à 
inalação de partículas ou gases nocivos. É ainda desconhecido o efeito da reabilitação 
respiratória neste tipo específico de células do sistema imunitário. Assim, os resultados 
deste estudo irão potencialmente contribuir para uma melhor compreensão da atividade 
celular imunitária estimulada pelo tratamento através da reabilitação respiratória da 
DPOC e futuros possíveis tratamentos para esta doença, de modo a contribuir para a 
qualidade de vida dos doentes. Para que seja possível alcançar estes objetivos vimos 
então solicitar a sua participação neste estudo que será realizado na Universidade de 
Aveiro. 
 
Porque é que fui escolhido? 
Foi escolhido/a porque é uma pessoa saudável ou com doença pulmonar obstrutiva 
crónica. Para o estudo, precisamos de dados de aproximadamente 20 pessoas, com uma 
condição clínica semelhante à sua, que aceitem participar. 
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Tenho de participar? 
A decisão de participar, ou não, é completamente sua. Se decidir participar vai-lhe ser 
pedido que assine um formulário de consentimento informado mas, é totalmente livre de 
desistir antes ou durante a recolha dos dados, sem que para tal tenha de dar qualquer 
justificação. A decisão de desistir ou de não participar, não afetará a qualidade dos 
serviços de saúde que lhe são prestados agora ou no futuro. 
 
O que me acontecerá caso decida participar? 
Após receber o consentimento informado devidamente assinado, será feita uma 
avaliação do seu estado de saúde geral. Primeiro, serão gravados os sons dos seus 
pulmões durante aproximadamente 20 segundos, com um microfone ligado a um 
computador portátil. Seguidamente, ser-lhe-á medido o peso e a altura e avaliada a força 
dos seus músculos da respiração e a capacidade respiratória, através de dois testes que 
consistem em inspirar e soprar para um equipamento. Depois, será avaliada a força dos 
seus músculos da coxa, pedindo-lhe quando está sentado que faça força procurando 
esticar a sua perna contra a mão de uma pessoa durante 6 segundos, e a sua tolerância 
ao exercício através de um teste de sentar e levantar de uma cadeira cinco vezes. Ser-
lhe-á também avaliada a sua expetoração e saliva, medida a quantidade de oxigénio no 
seu sangue, a sua frequência cardíaca, respiratória e tensão arterial. Ser-lhe-á também 
pedido que responda a um questionário para avaliar o seu nível de atividade física e que 
classifique a sua falta de ar, expetoração e tosse numa escala com diferentes graus. Por 
último ser-lhe-á colhido 20 mL de sangue por profissionais especializados e pedido que 
forneça expetoração para um frasco (este último passo apenas se aplica a doentes com 
DPOC; participantes saudáveis não fornecerão expetoração). Aos doentes com DPOC 
que ainda não tenham iniciado a reabilitação respiratória esta planeado fazer 2 colheitas 
de sangue e de expetoração (uma inicial e outra 12 semanas após o inicio da 
reabilitação) e nos indivíduos saudáveis e nos indivíduos com DPOC que não estão a 
fazer reabilitação respiratória, esta planeada também a realização de duas colheitas com 
um intervalo de 12 semanas. A iniciativa de fazer a primeira colheita, não implica a 
segunda, o paciente é totalmente livre de desistir de participar neste estudo a qualquer 
momento. A aplicação do protocolo terá a duração de aproximadamente 30 minutos. A 
dor e desconforto da colheita de sangue é a mesma de uma colheita de sangue para 
análises clínicas. 
 
Quais são os efeitos secundários, desvantagens e riscos se eu resolver participar?  
Os riscos serão os mesmos associados a uma colheita de sangue para análises clínicas. 
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Quais são os possíveis benefícios se eu resolver participar? 
Não existem benefícios diretos de participar no estudo. No entanto, a informação obtida 
neste estudo poderá ajudar a melhorar o diagnóstico e monitorização da DPOC, uma 
doença crónica que afeta cerca de 800.000 portugueses. 
 
A minha participação será confidencial?  
Toda a informação recolhida no decurso do estudo será mantida estritamente 
confidencial. Os dados recolhidos serão salvaguardados com um código e palavra-passe, 
para que ninguém o/a possa identificar. Apenas os investigadores do projeto terão 
acesso aos seus dados. 
 
O que acontecerá aos resultados do estudo? 
Os resultados do estudo serão analisados e incorporados numa Dissertação de Mestrado 
e alguns serão publicados em Jornais Científicos. No entanto, em nenhum momento o 
Sr./Sra. será identificado/a. Se gostar de obter uma cópia de qualquer relatório ou 
publicação, por favor diga ao investigador com quem contactar. 
 
Quem é que está a organizar e a financiar o estudo?  
O estudo decorre em parceria entre a Universidade de Aveiro e o Instituto de Biologia 
Molecular e Celular do Porto em colaboração com o Centro Hospitalar do Baixo Vouga. 
Este estudo não é financiado por nenhuma entidade.  
 
Quem fez a revisão do estudo? 
O estudo foi revisto e aprovado pela Comissão de Ética do Centro Hospitalar do Baixo 
Vouga e da Universidade de Aveiro. 
 
Contactos para mais informações sobre o estudo 
Prof. Fátima Macedo, Prof. Alda Marques 
Escola Superior de Saúde da Universidade de Aveiro, 
Telefone: 234372448; 234372462 
Secção Autónoma de Ciências da Saúde da Universidade de Aveiro 
e-mail: mfmacedo@ua.pt; amarques@ua.pt 
 
 
  
 
 
 
 
 
 
Annex II  
Informed consent 
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Termo de Consentimento Livre e Esclarecido 
Título do Projeto: Efeitos da Reabilitação Respiratória nos Linfócitos iNKT em 
pessoas com Doença Pulmonar Obstrutiva Crónica. 
Nome da Investigadora Responsável: Prof. Maria de Fátima Macedo 
Outros Investigadores do projeto: Prof. Alda Marques e Dr.ª Tânia Marante 
 
Por favor leia e assinale com uma cruz (X) os quadrados seguintes. 
1. Eu confirmo que percebi a informação que me foi dada e tive a 
oportunidade de questionar e de me esclarecer. 
 
2. Eu percebo que a minha participação é voluntária e que sou livre de 
desistir, em qualquer altura, sem dar nenhuma explicação, sem que isso 
afete qualquer serviço de saúde que me é prestado. 
3. Eu concordo que as recolhas de dados sejam fotografadas com o objetivo 
de ajudar no planeamento de futuros estudos e publicação em Revistas 
Científicas ou Congressos na área. 
 
4. Eu compreendo que os dados recolhidos durante o estudo são 
confidenciais e que só que só as 3 investigadoras do projeto terão acesso a 
eles. Portanto, dou autorização para que os mesmos tenham acesso a esses 
dados. 
 
5. Eu compreendo que os dados recolhidos durante o estudo podem ser 
utilizados para publicação em Revistas Científicas e usados noutras 
investigações, sem que haja qualquer quebra de confidencialidade. Portanto, 
dou autorização para a utilização dos dados para esses fins.  
 
 
 
 
 
________________________ 
Nome da pessoa 
                     
 
 
 
 
 
 
_________ 
Data 
 
 
 
 
 
___________________________ 
Assinatura 
 
 
________________________ 
Nome da Investigadora 
 
 
_________ 
Data 
 
 
___________________________ 
Assinatura 
  
 
 
 
 
 
 
Annex III  
Modified Borg scale 
Modified British Medical Research Council questionnaire 
COPD Assessment Test 
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Escala de Borg Modificada 
 
[119] (Borg, 1998) 
BORG, G. (1998) Borg's perceived exertion pain scale. Champaign. IL: Human Kinetics. 
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[120] DGS DGdS. Orientações Técnicas sobre Reabilitação Respiratória na Doença Pulmonar Obstrutiva Crónica (DPOC). In: 
Doença DdSdPeCd, editor. Lisboa2009 (adaptado). 
Questionário de Dispneia 
 
(Medical Research Council (MRC) Dyspnoea Questionnaire) 
 
Por favor, marque com uma cruz (X) o quadrado correspondente à 
afirmação que melhor descreve a sua sensação de falta de ar. 
 
 
  
 
GRAU 1 
Sem problemas de falta de ar excepto em caso de exercício físico 
intenso. 
“Só sinto falta de ar em caso de exercício físico intenso”. 
 
GRAU 2 
Falta de fôlego em caso de pressa ou ao percorrer um piso ligeiramente 
inclinado. 
“Fico com falta de ar ao apressar-me ou ao percorrer um piso 
ligeiramente inclinado”. 
 
GRAU 3 
Andar mais devagar que as restantes pessoas devido a falta de fôlego, 
ou necessidade de parar para respirar quando anda no seu passo 
normal. 
“Eu ando mais devagar que as restantes pessoas devido à falta de ar, 
ou tenho de parar para respirar quando ando no meu passo normal”. 
 
GRAU 4 
Paragens para respirar de 100 em 100 metros ou após andar alguns 
minutos seguidos. 
“Eu paro para respirar depois de andar 100 metros ou passado alguns 
minutos”. 
 
GRAU 5 
Demasiado cansado(a) ou sem fôlego para sair de casa, vestir ou 
despir. 
“Estou sem fôlego para sair de casa”. 
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Teste de Avaliação da DPOC – CAT 
Este questionário irá ajudá-lo a si e ao seu profissional de saúde a medir o impacto que a DPOC 
(Doença Pulmonar Obstrutiva Crónica) está a ter no seu bem-estar e no seu quotidiano. As suas 
respostas e a pontuação do teste podem ser utilizadas por si e pelo seu profissional de saúde 
para ajudar a melhorar a gestão da sua DPOC e a obter o máximo benefício do tratamento. Para 
cada um dos pontos a seguir, assinale com um (X) o quadrado que melhor o descreve 
presentemente. Certifique-se que seleciona apenas uma resposta para cada pergunta. 
Por exemplo: Estou muito feliz     0     1     2     3     4    5    Estou muito triste 
Nunca tenho tosse 0 1 2 3 4 5 Estou sempre a tossir 
Não tenho nenhuma 
expetoração 
(catarro) no peito 
0 1 2 3 4 5 
O meu peito está cheio 
de expetoração 
(catarro) 
Não sinto nenhum 
aperto no peito 
0 1 2 3 4 5 
Sinto um grande aperto 
no peito 
Não sinto falta de ar 
ao subir uma ladeira 
ou um lance de 
escadas 
0 1 2 3 4 5 
Quando subo uma 
ladeira ou um lance de 
escadas sinto bastante 
falta de ar 
Não sinto nenhuma 
limitação nas minhas 
atividades em casa 
0 1 2 3 4 5 
Sinto-me muito 
limitado nas minhas 
atividades em casa 
Sinto-me confiante 
para sair de casa, 
apesar da minha 
doença pulmonar 
0 1 2 3 4 5 
Não me sinto nada 
confiante para sair de 
casa, por causa da 
minha doença 
pulmonar 
Durmo 
profundamente 
0 1 2 3 4 5 
Não durmo 
profundamente devido 
à minha doença 
pulmonar 
Tenho muita energia 0 1 2 3 4 5 
Não tenho nenhuma 
energia 
Fonte: [122] George, F. H. M. (2013). Diagnóstico e Tratamento da Doença Pulmonar Obstrutiva Crónica.: Direção Geral de 
Saúde. 
 
Muito obrigado pela sua colaboração. 
 
